

CURRICULUM VITAE
JUDITH I. TSUI, MD, MPH

1. PERSONAL DETAILS:

Birthdate: September 23, 1968
 Birthplace: Summit, NJ
 Citizenship: United States Citizen

2. ACADEMIC TRAINING:

1986-1991 B.A., Princeton University, Princeton, NJ; Magna Cum Laude, Anthropology
 1993-1997 M.D., New York University School of Medicine, New York City, NY
 2002-2004 M.P.H., Rollins School of Public Health, Emory University, Atlanta, GA

3. POSTDOCTORAL TRAINING:

1997-1998 Intern, Oregon Health Sciences University, Portland, OR
 1998-2000 Resident, Oregon Health Sciences University, Portland, OR
 2004-2006 Research Fellow in General Internal Medicine, University of California, San Francisco, CA
 2006-2008 CTSA K12 Scholar, University of California, San Francisco, CA

4. ACADEMIC APPOINTMENTS:

2000-2002 Instructor in Medicine, Emory University School of Medicine, Atlanta, GA
 2002-2004 Assistant Professor of Medicine, Emory University School of Medicine, Atlanta, GA
 2004-2008 Instructor in Medicine, San Francisco VA Medical Center, San Francisco, CA
 2008-2014 Assistant Professor of Medicine, Boston University School of Medicine, Boston, MA
 2014-2016 Acting Assistant Professor of Medicine, University of Washington School of Medicine
 2016-2022 Associate Professor of Medicine, University of Washington School of Medicine, Seattle, WA
 2022-current Professor of Medicine, University of Washington School of Medicine, Seattle, WA
 2023--current Adjunct Professor, Health Services and Population Health, University of Washington

5. HOSPITAL APPOINTMENTS:

2000-2004 Attending Physician, Grady Memorial Hospital, Atlanta, GA
 2004-2008 Physician, San Francisco Veterans Affairs Administration, San Francisco, CA
 2008-2014 Attending Physician, Boston Medical Center, Boston, MA
 2014-current Attending Physician, Harborview Medical Center, Seattle, WA

6. LEADERSHIP POSITIONS:

2020-2022 Associate Medical Director, Adult Medicine-Evergreen Treatment Services (ETS) Clinic
 2020-current Associate Program Director, UW/Harborview Addiction Medicine Fellowship
 2020-current Program Director, UW Medical Student Addiction Research Program (R25)
 2022-current Director, UW GIM Substance Use Research and Education Unit

7. HONORS AND AWARDS:

1991 Magna Cum Laude, Princeton University
 1994 Stanley Foundation Research Award, NYU School of Medicine
 2002 Internal Medicine Wards Attending Teaching Award, Emory University School of Medicine
 2006 Bay Area Clinical Research Symposium Finalist for Best Abstract
 2007 Bay Area Clinical Research Symposium Finalist for Best Poster
 2015 Research paper selected for NIDA "Director's Report," by Dr. Nora Volkow
 2016 Research paper selected for NIDA "Director's Report," by Dr. Nora Volkow
 2019 Outstanding Research Mentor Award, UW Medical School Class of 2017
 2020 Nominated, UW School of Medicine Excellence in Mentoring Women Faculty Award 2020
 2023 Recipient of UW School of Medicine, Department of Medicine Gender Equity Award 2023

8. BOARD CERTIFICATION:

2000 Certified, American Board of Internal Medicine (re-certified 2021, expires 12/31/2031)
 2013 Certified, American Board of Addiction Medicine (expires 12/31/2023)

9. LICENSES TO PRACTICE

1998 State of Oregon Medical License #LL08914
 2000 State of Georgia Medical License #48945
 2004 State of California Medical License #A88353
 2008 State of Massachusetts Medical License #236710
 2014-current State of Washington Medical License #60511536

10. DIVERSITY, EQUITY, AND INCLUSION ACTIVITIES:

2020 “Breaking the Bias Habit®: A Workshop for Departments of Medicine”, UW Department of Medicine Workshop as part of the Bias Reduction in Internal Medicine (BRIM) Initiative, completed
 2021 “Search Committee Best Practices: Diversity = Excellence”, UW Center for Health Equity, Diversity & Inclusion Training, completed
 2021-current Harborview Opioid Treatment Network Diversity Equity and Inclusion Workgroup member
 2022-current UW GIM Leadership In Faculty Trajectory (LIFT) for Equity Initiative Committee member, a pilot initiative of the Gender Equity Council
 2023 Invited speaker/panelist for trainees of “Indigenous Substance use Prevention Interdisciplinary Research Education Program” (INSPIRE) to discuss opioid use disorder treatment for AI/AN populations.
 2023 UW Department of Medicine Gender Equity Award created to recognize and celebrate individuals who are dedicated to supporting the success of women and gender minorities.
<https://mednews.uw.edu/news/2023/gender-equity-awards>
 2023-current Committee Member, UW Medicine Disparities in Pain Medicine Task Force convened to identify ways to improve pain assessment and control, particularly for our minoritized and vulnerable patients
 2022-current Division of General Internal Medicine Women’s Physician Scientist Group member

11. PROFESSIONAL ORGANIZATIONS

2000-present Society of General Internal Medicine (SGIM)
 2002-2010 American College of Physicians (ACP)
 2013-2014 American Pain Society (APS)
 2013-present American Society of Addiction Medicine (ASAM)
 2013-present College on Problems of Drug Dependence (CPDD)
 2014-present Association for Medical Education and Research on Substance Abuse (AMERSA)

12. TEACHING EXPERIENCE AND RESPONSIBILITIES

A. Clinical Educational Activities

2000-2004 Medical Clinic Attending Teaching Physician, Grady Hospital
 2000-2004 Medical Ward Attending Teaching Physician, Grady Hospital
 2004-2008 Medical Clinic Attending Teaching Physician, SFVAMC
 2005-2006 Medical Ward Attending Teaching Physician, SFVAMC
 2008-2014 Medical Ward Attending Teaching Physician, Boston Medical Center
 2019-current Co-director, Capstone Transition to Residency course “Save Lives—Prescribe Buprenorphine”

B. Research Educational Activities

2012-2014 Director, Boston University General Internal Medicine Research in Progress Series
 2014-2018 Research Coach, Boston University/Yale University Research in Addiction Medicine Scholars Program (R25)
 2020-current Program Director/Curriculum Designer, UW Medical Student Addiction Research Program (R25)

C. Mentorship

Time Period	Mentee Name	Training Details	Deliverables
-------------	-------------	------------------	--------------

2011-2012	Lidia Meshesha, PhD Assistant Professor, University of Central Florida (current)	Research coordinator, Boston University School of Medicine	3 publications
2011-2013	Daniel Fuster, MD, PhD Associate Professor, Hospital Universitari Germans Trias I Pujol Barcelona, Spain (current)	Post-doctoral fellow, Boston University School of Medicine	4 publications
2011-present	Marlene Lira, MPH Senior Research Manager PhD candidate, Johns Hopkins School of Public Health (current)	Research coordinator, Boston University School of Medicine	2 publications
2012-2013	Denise Crooks, MPH Psychotherapist and Social Worker (current)	Research coordinator, Boston University	1 publication
2012-2013	Ji Mao, MSc JD	MSc Student	Master's thesis
2012-2016	Katelyn Carey, MD MPH OB/Gyn resident, University of Rochester (current)	Medical Student, Boston University	1 conference abstract, 1 publication
2015-2017	Claire Simon, MD Family Practice resident, University of Washington (current)	Medical Student, University of Washington	1 publication
2016-2018	Jennifer Wagman, PhD Assistant Professor UCLA Fielding School of Public Health (current)	Post-doctoral fellow, University of California, San Diego	2 conference abstracts, 3 publications
2016-2019	Bjorn Payne, MD Psychiatry resident, Cambridge Health Alliance (current)	Medical student, University of Washington	1 conference abstract, 1 publication
2016-2018	Margo Godersky, MPH Project Manager Surgical Outcomes Research Center Department of Surgery, University of Washington (current)	Research Coordinator, Section of GIM, Dept of Medicine, University of Washington	2 publications
2016-present	Jocelyn James, MD Assistant Professor Division of General Internal Medicine, Department of Medicine, University of Washington (current)	Junior faculty, Section of GIM, Dept of Medicine, University of Washington	2 conference abstracts, 3 publications, co-I on grant with WA State DOH (PI: Tsui); career mentoring
2016-present	Jared Klein, MD, MPH, Associate Professor Division of General Internal Medicine, Department of Medicine, University of Washington (current)	Junior faculty, Section of GIM, Dept of Medicine, University of Washington	5 publications, 4 conference abstracts, 2 SAMHSA grants, co-I on R25 (PI: Tsui)
2017-present	James Darnton, MD Clinical Assistant Professor Division of General Internal Medicine, Department of Medicine, University of Washington	Junior faculty, Section of GIM, Dept of Medicine, University of Washington	1 conference abstract, co-I on R41 (PI: Tsui) 2 manuscripts published
2018-present	Natasha Ludwig-Baron, MPH PhD student	PhD candidate, Epidemiology, University of Washington	1 conference abstract, 1 publication, 1 manuscript submitted

	Department of Epidemiology, University of Washington		
2018-2021	Belle Ngo, BA Medical Student University of Washington School of Medicine/Underserved Pathways	Medical student, University of Washington	2 conference oral abstract, 2 publications
2019-2020	Julian Takagi-Stewart Undergraduate student University of Toronto, mentored through HIPRC's INSIGHT program (R25)	Pre-medical student, University of Toronto	1 conference poster, 1 paper
2019-2021	Maria Corcorran, MD, MPH Acting Clinical Instructor Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington	Junior faculty, Section of Infectious Diseases, Dept of Medicine, University of Washington	2 conference abstracts, 4 publications; career mentoring
2019-present	Elenore Bhatraju, MD, MPH Assistant Professor Division of General Internal Medicine, Department of Medicine, University of Washington	Junior faculty, Section of GIM, Dept of Medicine, University of Washington	4 publications, primary mentor for K award submitted 10/2022 to NIDA/NIH pending funding
2019-present	Michael Barry, BA PhD student Department of Epidemiology, University of Washington	PhD candidate, Epidemiology, University of Washington	1 manuscript under review, thesis in preparation
2020-2021	Julie Skene, MSN Masters student Department of Global Health, University of Washington	MPH candidate Global Health, University of Washington	Thesis committee member
2020-present	Zoe Kratina-Hathaway, BA Medical student and MedStAR R25 trainee University of Washington School of Medicine	Medical Student, University of Washington	MedStAR R25 trainee; 2 conference abstracts; 1 manuscript
2020-2022	Anisha Ganguly, MD MPH Medical resident Internal Medicine Residency University of Washington School of Medicine	Medical resident, University of Washington	1 publication Received Hopkins GIM Lisa A. Cooper - David M. Levine Award for paper
2020-2021	Elissa Poorman, MD, MPH Clinical fellow Addiction Medicine fellowship, Department of Medicine, University of Washington School of Medicine	Addiction Medicine fellow, University of Washington	1 publication
2020-2021	Simeon Kimmel, MD, MA Assistant Professor Division of General Internal Medicine, Department of Medicine, Boston University School of Medicine	Junior faculty, Boston University	1 publication

2021-present	Brittany Blanchard, PhD Acting Assistant Professor Department of Psychiatry and Behavioral Sciences University of Washington	KL2 scholar, University of Washington	Co-mentor on KL2 award
2021-present	Helen Jack, MD Acting Assistant Professor Division of General Internal Medicine Department of Medicine University of Washington	Junior faculty, K23 awardee	Co-mentor on K23 award
2022-present	Omeid Heidari, PhD, MPH, ANP-C, Assistant Professor University of Washington School of Nursing	Junior faculty	Primary mentor on KL2 award
2022-present	Kaitlin Zinsli, MPH School of Public Health, Department of Epidemiology University of Washington	PhD Student	Thesis committee member Co-mentor
2022-present	Bulat Isidrov, MD MSc School of Public Health, Department of Population Health and Health Services	PhD Student	1 publication
2022-present	Che Ross Medical student and MedStAR R25 trainee University of Washington School of Medicine	Medical Student, University of Washington	MedStAR R25 trainee; 1 conference abstracts
2019-present	Elenore Bhatraju, MD, MPH Assistant Professor Division of General Internal Medicine, Department of Medicine, University of Washington	Junior faculty, Section of GIM, Dept of Medicine, University of Washington	11 publications, Primary mentor for K award (K23DA058751-01)

D. Invited Talks

See section 18: Invited Lectures and Presentations

13. EDITORIAL RESPONSIBILITIES

2012-2013 Associate Editor, *Alcohol, Other Drugs, and Health: Current Evidence*

2019-2023 Academic Editor, *Plos One*

14. SPECIAL NATIONAL RESPONSIBILITIES**A. GRANT STUDY SECTIONS**

NIH/NIDA study section ZRG1 AARR-H PAR Panel, December 10, 2015

NIH/NIDA study section ZDA1 HXO-H Panel, November 30, 2018

NIH/NIDA study section ZDA1 GXM-A Panel, February 19, 2019

NIH/NIDDK study section ZDK1 GRB-M Panel, August 6, 2019

NIH/NIDA IPTA study section, June 5 and 6, 2020

NIH/NIDA IPTA study section, June 7 and 8, 2021

NIH/NIMH study section ZMH1 ERB-G (08) R, June 29, 2021

NIH/NIDA study section 2022/10 ZDA1 SKM-D(01) S June 9 and June 17, 2022

NIH/NIDA study section HEAL RFA-DA-23-053, RFA-DA-23-054, February 10, 2023

NIH/NIDA study section for RFA-DA-24-010, June 5, 2023

B. NATIONAL BOARD MEMBERSHIPS/COMMITTEES/OTHER

2004-2006	Founder, Society of General Internal Medicine HCV Interest Group
2013-2014	Society of General Internal Medicine, National Meeting Scientific Abstract Reviewer
2018-2019	Association for Medical Education and Research on Substance Abuse National Meeting Abstract Reviewer
2018	Society for General Internal Medicine Lawrence S. Linn Award Selection Committee
2019-current	Global Task Force for Chronic Pain in People with HIV
2019-2022	College for Problems of Drug Dependence National Membership Committee
2019-2020	Society for Behavioral Medicine Scientific Abstract Reviewer for 2020 National Meeting
2020	American College of Academic Addiction Medicine Poster Planning and Selection Committee
2021-current	Steering Committee, Inter-CFAR Substance Use Research Community (I-SURC)
2021-current	Scientific Advisory Committee, UW Behavioral Research Center for HIV (BIRCH)
2021-current	HIV Prevention Trials Network 0094 Study Monitoring Committee
2022-current	Hepatitis Education Project, Board of Directors
2022-current	AMERSA Scientific Abstract reviewer for 2022 and 2023 National Meeting
2022-current	Advisory Committee, Boston Medical Center Clinical Addiction Research and Education (CARE) Program
2022-current	ED-LINC (PI: Whiteside) member of Data Safety Monitoring Board

15. SPECIAL LOCAL RESPONSIBILITIES:

2002-2004	Member, Grady Memorial Hospital Pain Committee
2002-2004	Founding Member, Grady Hospital Liver Clinic
2008-2014	Buprenorphine Provider, Office Based Opioid Treatment (OBOT) Program, Boston Medical Center
2011-2014	Founder, Hepatitis C Treatment OBOT Program, Boston Medical Center
2014-2015	Co-Director, Hepatitis C Virus Outcomes Among Substance Users, Pre-Affinity Research Collaborative (Pre-ARC), Evans Center for Interdisciplinary Biomedical Research
2015-2020	Founding member and physician provider of Harborview Medical Center's Office Based Opioid Treatment Program (OBOT) established 12/2015
2016-current	Founding member of HMC's satellite Primary Care Clinic at Evergreen Treatment Services, established 7/2016
2016	Resident Conference/Academic Half-Day on Hepatitis C
2018-current	Member of the WA State Hepatitis C Elimination Coordinating Committee, assembled to assist Governor Jay Inslee achieve his statewide initiative to eliminate Hepatitis C by 2030
2019-2023	Faculty, Center for AIDS Research (CFAR) Behavioral Science Core at the University of Washington
2020-current	Drug User Health Equity Workgroup Member
2021-current	Overdose Emergency and Innovative Recovery Task Force Member, VOCAL-WA
2021-current	Bree Collaborative Hepatitis C Workgroup, WA State
2023-current	Interim Medical Director, Hepatitis Education Project
2023-current	UWSOM Department of Medicine Research Workgroup member
2023-current	Director, CFAR Substance Use Scientific Working Group

16. RESEARCH FUNDING

A. CURRENT

2014-2025	Clinical Trials Network: Pacific Northwest Node (Hatch-Maillette, Donovan – MPI) NIH/NIDA (5UG1DA013714) Total Funding: \$3,645,023 Role: Co-Investigator
2019-2025	Rural Comorbidity and HIV Consequences of Opioid use Research and Treatment Initiative (Rural cohort) (H. Crane, Tsui – MPI) NIH (1U24DA048538) Total Funding: \$3,717,717 Role: PI
2020-2025	The UW Medical Student Addiction Research (MedStAR) Program to Address Substance Use and Disorders in Urban and Rural Communities in Five Western States (Tsui – PI) NIH (1R25DA050985)

- Total Funding: \$1,874,852
Role: PI
- 2020-2025 **HRSA UW Addiction Medicine Fellowship** (Merrill – PI)
HRSA (1T25HP376280100)
Total Funding: \$1,343,071
Role: Associate Program Director, Co-Investigator
- 2020-2025 **Indigenous Substance use Prevention Interdisciplinary Research Education Program** (Evans-Campbell, Johnson-Jennings – PI)
NIH (1R25DA051343)
Total Funding: \$1,012,495
Role: Co-Investigator
- 2022-2027 **Gabapentin to Reduce Alcohol and Improve Viral Load Suppression – Promoting Treatment as Prevention** (Samet, Lunze – PI)
NIH/NIAAA (R01AA030460)
Total Funding: \$3,848,159 (Subaward)
Role: Subaward PI
- 2022-2026 **Practice facilitation and supervision to strengthen depression treatment in primary care in Zimbabwe** (Jack – PI)
NIH/NIMH (K23MH129420)
Total Funding: \$939,836
Role: Co-Mentor
- 2022-2025 **Patient Navigator plus Remote mHealth Adherence Support with Incentives to Improve Linkage and Retention among Hospitalized Patients with Opioid and Methamphetamine Use who Initiate Buprenorphine** (Tsui – PI)
NIH/NIDA (1R34DA057609)
Total Funding: \$699,750
Role: PI
- 2022-2024 **Clinical Trials Network: CTN-0110 Randomized, Double-Blind, Placebo-Controlled Trial of Monthly Injectable Buprenorphine for Methamphetamine Use Disorder (MURB)** (Trivedi, Shoptaw – MPI)
NIH/NIDA (UG1 DA020024)
Total Funding: \$782,819
Role: Project/Subaward PI
- 2022-2025 **Special Projects Collaborative - Opioid Use Disorder (SPC-OUD)** (Tamru – PI)
SAMHSA (H79TI085075)
Total Funding: \$1,125,000
Role: Medical Co-Director
- 2021-2026 **The Harborview Medical Center Medication Assisted Treatment-Prescription Drug and Opioid Addiction Project (HMC MAT-PDOA)** (Tamru – PI)
SAMHSA (H79TI084347)
Total Funding: \$2,625,000
Role: Medical Co-Director
- 2023-2028 **Training in Equity and Structural Solutions in Addictions (TESSA)** (Williams, Tsui, Chander – MPI)
NIH/NIDA (T32DA057920)
Total Funding: \$1,368,512
Role: PI
- 2023-2027 **Building and Implementing Best Practices for Buprenorphine Initiation in the Setting of Fentanyl Use** (Bhatraju – PI)
NIH/NIDA (K23DA058751-01)
Total Funding: \$939,838
Role: Primary Mentor
- 2023-2026 **Addressing Loneliness in Primary Care Patients on Chronic Opioids to Prevent Opioid Misuse** (Tong – PI)
NIH/NIDA (R34)

- Total Funding: \$450,000
Role: Co-Investigator
- 2023-2026 **Video observed therapy to enhance flexibility and reduce in-person visits for patients treated with methadone in a multi-site opioid treatment program** (Tsui, Hallgren, Seiguer – MPI)
NIH/NIDA (R44DA053081)
Total Funding: \$1,867,981
- 2023-2028 **Systems analysis and improvement to optimize opioid use disorder care quality and continuity for patients exiting jail (SAIA-MOUD)** (Gimbel – PI)
NIH/NINR (R01 NR021102)
Total Funding: \$450,000
Role: Co-Investigator
- 2024-2025 **A Community Pharmacist-led Collaborative Care Program to Provide Syndemic Care for People Who Use Drugs** (Tsui – PI)
Washington State Department of Health (WS DOH)
Total Funding: \$100,000
Role: PI
- 2023-2027 **Supporting Unhealthy Substance use care Through a whole person Approach and user centered INtegration into primary care (SUSTAIN)** (Tong – PI)
AHRQ (R18)
Total Funding: \$2,500,000
Role: Co-Investigator
- 2023-2028 **UW/Fred Hutch Center for AIDS Research** (Cellum—PI)
NIH (P30 AI027757)
Total Funding: \$17,908,687
Role: Co-I/Substance Use Scientific Working Group Director

B. PENDING

- 2023-2027 **The Influence of Race, Ethnicity, and Geography in the Delivery of Community Pharmacy Opioid Harm Reduction Services** (Hughes, Tamera – PI)
NIH/NIDA (1K99DA058766-01)
Role: Co-Mentor
- 2024-2029 **Telehealth Behavioral Harm Reduction Treatment Support for Substance Use Disorder (TeleHaRTS)** (Collins – PI)
NIH (grant number pending)
Role: Co-Investigator
- 2024-2027 **HCV Elimination in PWID in the United States: HERO in practice** (Litwin – PI)
PCORI (grant number pending)
Role: Co-Investigator

C. PAST

- 2021-2023 **University of Washington Regional Buprenorphine Training Program** (Klein – PI)
SAMHSA (1H79TI083996)
Total Funding: \$446,751
Role: Co-Investigator
- 2021-2023 **The Center of Biomedical Research Excellence (COBRE) on Opioids and Overdose** (Rich – PI)
NIH/NIGMS (P20GM125507-01)
Total Funding: \$12,388,706
Role: External Advisory Committee Member
- 2019-2023 **Pilot Study of a Community-Pharmacy Model to Expand Access to Medications to Treat and Prevent Hepatitis C, Opioid Use Disorders, Overdose and HIV among Persons Who Inject Drugs** (Tsui – PI)
NIH (1R34DA047660)
Total Funding: \$643,770

- 2019-2023 **HIV Researchers Mentoring the Next Generation of Addiction Clinician** scientists (Fairbairn – PI)
NIH (R25-DA037756)
Total Funding: \$2,212,003
Role: Co-Investigator
- 2018-2023 **University of Washington/Fred Hutch Center for AIDS Research** (Simoni – PI)
NIH/NIAID (P30AI027757)
Total Funding: \$3,727,920
Role: Faculty
- 2018-2023 **Genes, Substance Use, and HIV Outcomes in People Living with HIV across the US** (H. Crane, Peter – MPI)
NIH/NIDA (1R01DA047045)
Total Funding: \$4,068,885
Role: Co-Investigator
- 2017-2023 **Pilot Study of Opioid-receptor Antagonists to Reduce Pain and Inflammation among HIV-Infected Persons with Alcohol** (Tsui, Samet – MPI)
NIH/NIAAA (UH2AA026193)
Total Funding: \$1,035,733
- 2018-2022 **Mindful Body Awareness Training as an Adjunct to Medication Assisted Treatment for Opioid Use Disorder** (Price, Merrill – MPI)
NIH/NCCHI (1R33AT009932)
Total Funding: \$738,950
Role: Other Significant Contributor (de minimis)
- 2020-2022 **Collaborative Care Management for Integrated Mental Health and Substance Use Treatment in Low-Barrier HIV Care** (Dombrowski – PI)
NIH/NIDA (1R34MH124625)
Total Funding: \$677,799
Role: Co-Investigator
- 2020-2022 **Feasibility of mHealth technology-enabled service for remote observed therapy of methadone and COVID-19 screening for patients in an opioid treatment program** (Tsui, Seiguer – MPI)
NIH/NIDA (1R41DA053081)
Total Funding: \$224,940
- 2016-2022 **Patient-Centered Models of HCV Care for People who Inject Drugs** (Litwin – PI)
PCORI (HPC-1503-28122)
Total Funding: \$15,719,819
Role: Subaward PI
- 2020-2021 **Training Buprenorphine Prescribers to Manage Chronic Hepatitis C Among Persons with Opioid Use Disorders** (Tsui – PI)
Washington State Department of Health (DOH) (HED25083)
Total Funding: \$11,638
- 2019-2021 **Evaluating Practice Facilitation to Optimize Alcohol-Related Care and HCV Treatment Outcomes in HCV Treatment Settings** (Williams – PI)
Puget Sound Healthcare System VA (IIR-17-120-3)
Total Funding: \$1,099,670
Role: Co-Investigator
- 2017-2021 **Development and Evaluation of Effectiveness of Video-Based Directly Observed Therapy for Office-Based Treatment of Opioid Use Disorders with Buprenorphine** (Tsui, Seiguer – MPI)
NIH (R44DA044053)
Total Funding: \$1,580,484
- 2018-2021 **University of Washington Provider's Clinical Support System – Universities** (Klein, Tsui – MPI)
SAMHSA (1H79TI081651)
Total Funding: \$444,583
- 2016-2021 **3/4 Alcohol Research Consortium in HIV – Epidemiological Research Arm (ARCH-ERA)** (H. Crane, Lau – MPI)
NIH/NIAAA (U01AA020793)

- Annual Direct Costs: \$568,690
Role: Co-Investigator
- 2018-2020 **Medication-First Delivery for High-Acuity Opioid Use Disorder Populations** (Banta-Green – PI)
The Paul G. Allen Family Foundation (12844)
Role: Advisor
- 2014-2020 **Improving Physician Opioid Prescribing for Chronic Pain in HIV-infected Persons** (Samet, del Rio – PI)
NIH/NIDA (1R01DA037768)
Role: Co-Investigator
- 2017-2019 **Integrating Addiction Research in Health Systems: The Addiction Research Network** (Campbell, Bradley, Weisner – MPI)
NIH/NIDA (3UG1DA040314-03S3)
Role: Co-Investigator
- 2015-2019 **Extracellular Vesicles in Semen and Genital HIV Infection and Immunity during Heroin Addiction and Methadone or Buprenorphine Substitution Therapy** (Hladik – PI)
NIH/NIDA (1R01DA040386)
Role: Co-Investigator
- 2017-2019 **Oregon HIV/Hepatitis and Opioid Prevention and Engagement (OR-HOPE) Study** (Korthuis – PI)
NIH/NIH (UG3DA044831)
Role: Co-Investigator
- 2016-2018 **WA State Innovation Initiative – Medication Assisted Treatment Upon Release from Prison** (Banta-Green – PI)
Laura and John Arnold Foundation (no grant #)
Role: Co-Investigator
- 2015-2018 **SAMHSA Medication-Assisted Treatment** (Merrill – PI)
SAMHSA (1512-47681)
Role: Co-Investigator
- 2017-2018 **Qualitative Study of Patient and Provider Attitudes Toward Video-Based Directly Observed Therapy (vDOT) for Office-Based Treatment of Opioid Use Disorders with Buprenorphine** (Tsui – PI)
UW Alcohol & Drug Abuse Institute (no grant #)
- 2012-2018 **Advancing Clinical Research Training within Addiction Residency Programs** (Samet, O’Connor – MPI)
NIH NIDA (5R25DA033211-05)
Role: Co-Investigator
- 2016-2017 **Zinc for HIV Disease among Alcohol Users – An RCT in the Russia ARCH Cohort** (Samet – PI)
NIH NIAAA (U01AA021989-05S1)
Role: Co-Investigator
- 2011-2016 **International Collaborative of Prospective Studies of HIV and Hepatitis in IDU** (Page – PI)
NIH NIDA (5R01DA031056-06)
Role: Co-Investigator
- 2011-2015 **Linking Russian Narcology & HIV Care to Enhance Treatment, Retention, & Outcomes (LINC)** (Samet – PI)
NIH NIDA (R01DA032082)
Role: Co-Investigator
- 2010-2015 **HCV and Pain in Substance Users with and without HIV** (Tsui – PI)
NIH/NIDA (5K23DA027367)

17. BIBLIOGRAPHY

A. ORIGINAL, PEER-REVIEWED MANUSCRIPTS

1. **Tsui JI**, Dodson K, Jacobson TA. Cardiovascular disease prevention counseling in residency: resident and attending physician attitudes and practices. J Natl Med Assoc. 2004;96(8):1080-3:1088-91. PMID: PMC2568499.

2. **Tsui JI**, Pletcher MJ, Vittinghoff E, Seal K, Gonzales R. Hepatitis C and hospital outcomes in patients admitted with alcohol-related problems. *J Hepatol.* 2006;44(2):262-6. PMID: 16226823.
3. **Tsui JI**, Vittinghoff E, Shlipak MG, O'Hare AM. Relationship between hepatitis C and chronic kidney disease: results from the Third National Health and Nutrition Examination Survey. *J Am Soc Nephrol.* 2006;17(4):1168-74. PMID: 16524948.
4. **Tsui JI**, Bangsberg DR, Ragland K, Hall CS, Riley ED. The impact of chronic hepatitis C on health-related quality of life in homeless and marginally housed individuals with HIV. *AIDS Behav.* 2007;11(4):603-10. PMID: 17028996.
5. **Tsui JI**, Saitz R, Cheng DM, Nunes D, Libman H, Alperen JK, Samet JH. Awareness of hepatitis C diagnosis is associated with less alcohol use among persons co-infected with HIV. *J Gen Intern Med.* 2007;22(6):822-5. PMCID: PMC2048689.
6. **Tsui JI**, Vittinghoff E, Shlipak MG, Bertenthal D, Inadomi J, Rodriguez RA, O'Hare AM. Association of hepatitis C seropositivity with increased risk for developing end-stage renal disease. *Arch Intern Med.* 2007;167(12):1271-6. PMID: 17592100.*
7. **Tsui JI**, French AL, Seaberg EC, Augenbraun M, Nowicki M, Peters M, Tien PC. Prevalence and long-term effects of occult hepatitis B virus infection in HIV-infected women. *Clin Infect Dis.* 2007;45(6):736-40. PMCID: PMC4142488.
8. **Tsui JI**, Currie S, Shen H, Bini EJ, Brau N, Wright TL; VA HCV-001 Study Group. Treatment eligibility and outcomes in elderly patients with chronic hepatitis C: results from the VA HCV-001 Study. *Dig Dis Sci.* 2008;53(3):809-14. PMID: 17823868.
9. **Tsui JI**, Maselli J, Gonzales R. Sociodemographic trends in national ambulatory care visits for hepatitis C virus infection. *Dig Dis Sci.* 2009;54(12):2694-8. PMCID: PMC2778662.
10. **Tsui J**, Vittinghoff E, Anastos K, Augenbraun M, Young M, Nowicki M, Cohen MH, Peters MG, Golub ET, Szczech L. Hepatitis C seropositivity and kidney function decline among women with HIV: data from the Women's Interagency HIV Study. *Am J Kidney Dis.* 2009;54(1):43-50. PMCID: PMC2997705.
11. **Tsui JI**, Whooley MA, Monto A, Seal K, Tien PC, Shlipak M. Association of hepatitis C virus seropositivity with inflammatory markers and heart failure in persons with coronary heart disease: data from the Heart and Soul study. *J Card Fail.* 2009;15(5):451-6. PMCID: PMC2782758.
12. **Tsui JI**, Vittinghoff E, Hahn JA, Evans JL, Davidson PJ, Page K. Risk behaviors after hepatitis C virus seroconversion in young injection drug users in San Francisco. *Drug Alcohol Depend.* 2009;105(1-2):160-3. PMCID: PMC2849721.*
13. **Tsui JI**, Herman DS, Kettavong M, Alford D, Anderson BJ, Stein MD. Physician introduction to opioids for pain among patients with opioid dependence and depressive symptoms. *J Subst Abuse Treat.* 2010;39(4):378-83. PMCID: PMC3129653.
14. **Tsui JI**, Herman DS, Kettavong M, Anderson BJ, Stein MD. Chronic pain and hepatitis C virus infection in opioid dependent injection drug users. *J Addict Dis.* 2011;30(2):91-7. PMCID: PMC3089758.
15. **Tsui JI**, Herman DS, Kettavong M, Anderson BJ, Stein MD. Escitalopram is associated with reductions in pain severity and pain interference in opioid dependent patients with depressive symptoms. *Pain.* 2011;152(11):2640-4. PMCID: PMC3235744.
16. Evans JL, **Tsui JI**, Hahn JA, Davidson PJ, Lum PJ, Page K. Mortality among young injection drug users in San Francisco: a 10-year follow-up of the UFO Study. *Am J Epidemiol.* 2012;175(4):302-8. PMCID: PMC3271816.
17. **Tsui JI**, Cheng DM, Libman H, Bridden C, Samet JH. Hepatitis C virus infection is associated with painful symptoms in HIV-infected adults. *AIDS Care.* 2012;24(7):820-7. PMCID: PMC3370099.
18. **Tsui JI**, Cheng DM, Libman H, Bridden C, Saitz R, Samet JH. Risky alcohol use and serum aminotransferase levels in HIV-infected adults with and without hepatitis C. *J Stud Alcohol Drugs.* 2013;74(2):266-70. PMCID: PMC3568165.
19. Fuster D, **Tsui JI**, Cheng DM, Quinn EK, Armah KA, Nunes D, Freiberg MS, Samet JH. Interleukin-6 is associated with noninvasive markers of liver fibrosis in HIV-infected patients with alcohol problems. *AIDS Res Hum Retroviruses.* 2013;29(8):1110-16. PMCID: PMC3715787.
20. Fuster D, **Tsui JI**, Cheng DM, Quinn EK, Bridden C, Nunes D, Libman H, Saitz R, Samet JH. Impact of lifetime alcohol use on liver fibrosis in a population of HIV-infected patients with and without hepatitis C coinfection. *Alcohol Clin Exp Res.* 2013;37(9):1527-35. PMCID: PMC3758457.

21. **Tsui JI**, Cheng DM, Coleman SM, Blokhina E, Bridden C, Krupitsky E, Samet JH. Pain is associated with heroin use over time in HIV-infected Russian drinkers. *Addiction*. 2013;108(10):1779-87. PMCID: PMC4012755.
22. Meshesha LZ, **Tsui JI**, Liebschutz JM, Crooks D, Anderson BJ, Herman DM, Stein MD. Days of heroin use predict poor self-reported health in hospitalized heroin users. *Addict Behav*. 2013;38(12):2884-7. PMCID: PMC3882159.
23. Fuster D, Cheng DM, Quinn EK, Nunes D, Saitz R, Samet JH, **Tsui JI**. Chronic hepatitis C virus infection is associated with all-cause and liver-related mortality in a cohort of HIV-infected patients with alcohol problems. *Addiction*. 2014;109(1):62-70. PMCID: PMC3947001.
24. Fuster D, Cheng DM, Quinn EK, Armah KA, Saitz R, Freiberg MS, Samet JH, **Tsui JI**. Inflammatory cytokines and mortality in a cohort of HIV-infected adults with alcohol problems. *AIDS*. 2014;28(7):1059-64. PMCID: PMC4105144.*
25. **Tsui JI**, Cheng DM, Coleman SM, Lira MC, Blokhina E, Bridden C, Krupitsky E, Samet JH. Pain is associated with risky drinking over time among HIV-infected persons in St. Petersburg, Russia. *Drug Alcohol Depend*. 2014;144:87-92. PMCID: PMC4252482.
26. **Tsui JI**, Evans JL, Lum PJ, Hahn JA, Page K. Association of opioid agonist therapy with lower incidence of hepatitis C virus infection in young adult injection drug users. *JAMA Intern Med*. 2014;174(12):1974-81. PMCID: PMC4506774.*
27. **Tsui JI**, Anderson BJ, Strong DR, Stein MD. Craving predicts opioid use in opioid-dependent patients initiating buprenorphine treatment: a longitudinal study. *Am J Drug Alcohol Abuse*. 2014;40(2):163-9. PMCID: PMC4868341.
28. Crooks D, **Tsui J**, Anderson B, Dossabhoy S, Herman D, Liebschutz JM, Stein MD. Differential risk factors for HIV drug and sex risk-taking among non-treatment-seeking hospitalized injection drug users. *AIDS Behav*. 2015;19(3):405-11. PMCID: PMC4861062.
29. **Tsui JI**, Lira MC, Cheng DM, Winter MR, Alford DP, Liebschutz JM, Mao J, Edwards RR, Samet JH. Hepatitis C virus infection and pain sensitivity in patients on methadone or buprenorphine maintenance therapy for opioid use disorders. *Drug Alcohol Depend*. 2015;153:286-92. PMCID: PMC4509826.*
30. Liebschutz JM, Crooks D, Herman D, Anderson BJ, **Tsui JI**, Meshesha LZ, Dossabhoy S, Stein MD. Buprenorphine treatment for hospitalized, opioid-dependent patients: a randomized clinical trial. *JAMA Int Med*. 2014 Aug;174(8):1369-76. PMCID: PMC4811188.
31. Page K, **Tsui JI**, Maher L, Choopanya K, Vanichseni S, Mock PA, Celum C, Martin M. Biomedical HIV prevention including pre-exposure prophylaxis and opiate agonist therapy for women who inject drugs: state of research and future directions. *J Acquir Immune Defic Syndr*. 2015 Jun 1;69 Suppl 2:S169-75. PMCID: PMC4491435.
32. **Tsui JI**, Cheng DM, Sisson EK, Bridden C, Merlin JS, Saitz R, Samet JH. Pain and mortality risk in a cohort of HIV-infected persons with alcohol use disorders. *AIDS and Behaviors*. *AIDS Behav*. 2016 Mar;20(3):583-9. PMCID: PMC4777650.
33. Carey K, Huang W, Linas BP, **Tsui JI**. Hepatitis C virus testing and treatment among persons receiving buprenorphine in an office-based program for opioid use disorders. *J Subst Abuse Treat*. 2016 Jul;66:54-9. PMCID: PMC5097249.
34. **Tsui JI**, Lira M, Cheng DM, Winter MR, Alford DP, Liebschutz JM, Edwards RR, Samet JH. Chronic pain, craving, and illicit opioid use among patients receiving opioid agonist therapy. *Drug Alcohol Depend*. 2016 Sep 1;166:26-31. PMCID: PMC4983520.
35. Ioannou GN, Beste LA, Chang MF, Green PK, Lowey E, **Tsui JI**, Su F, Berry K. Effectiveness of Sofosbuvir, Ledipasvir/Sofosbuvir, or Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir regimens for treatment of patients with hepatitis C in the Veterans Affairs National Health Care System. *Gastroenterology*. 2016 Sep;151(3):457-471. PMCID: PMC5341745.
36. **Tsui JI**, Ko S, Krupitsky E, Lioznov D, Chaisson CE, Gnatenko N, Samet JH. Insights on the Russian HCV care cascade: minimal HCV treatment for HIV/HCV co-infected PWID in St. Petersburg. *Hepatol Med Policy*. 2016;1. PMCID: PMC5313079.
37. **Tsui JI**, Williams EC, Green PK, Berry K, Su F, Ioannou GN. Alcohol use and hepatitis C virus treatment outcomes among patients receiving direct antiviral agents. *Drug Alcohol Depend*. 2016 Dec 1;169:101-109. PMCID: PMC6534140.

38. **Tsui JI**, Cheng DM, Coleman SM, Blokhina E, Gnatienco N, Bryant K, Krupitsky E, Zvartau E, Samet JH. Pain and risk behaviors among HIV-infected persons in St. Petersburg, Russia. *AIDS Behav.* 2017 Jun;21(6):1775-1781. PMCID: PMC5408303.
39. **Tsui JI**, Mirzazadeh A, Hahn JA, Maher L, Bruneau J, Grebely J, Hellard M, Kim AY, Shoukry NH, Cox AL, Prins M, Dore G, Lauer G, Lloyd A, Page K. The effects of alcohol on spontaneous clearance of acute hepatitis c virus infection in females versus males. *Drug Alcohol Depend.* 2016 Dec 1;169:156-162. PMCID: PMC5328754.
40. Lasser KE, Heinz A, Battisti L, Akoumianakis A, Truong V, **Tsui JI**, Ruiz G, Samet JH. A hepatitis C treatment program based in a safety-net hospital patient-centered medical home. *Ann Fam Med.* 2017 May;15(3):258-261. PMCID: PMC5422088.
41. **Tsui JI**, Burt R, Thiede H, Glick SN. Utilization of buprenorphine and methadone among opioid users who inject drugs. *Subst Abus.* 2018 Jan 2;39(1):83-88. PMCID: PMC6467071.*
42. Simon CB, **Tsui JI**, Merrill JO, Adwell A, Tamru E, Klein JW. Linking patients with buprenorphine treatment in primary care: predictors of engagement. *Drug Alcohol Depend.* 2017 Dec 1;181:58-62. PMID: 29035705.
43. Owens MD, Ioannou GN, **Tsui JI**, Edelman EJ, Greene PA, Williams EC. Receipt of alcohol-related care among patients with HCV and unhealthy alcohol use. *Drug Alcohol Depend.* 2018 Jul 1;188:79-85. PMCID: PMC5999587.
44. Wagman JA, Samet JH, Cheng DM, Gnatienco N, Raj N, Blokhina E, Toussova OV, Forman LS, Lioznov D, **Tsui JI**. Female gender and HIV transmission risk behaviors among people living with HIV who have ever used injection drugs in St. Petersburg, Russia. *AIDS Behav.* 2018 Sep;22(9):2830-2839. PMCID: PMC6128669.
45. Assoumou SA, Wang J, Tasillo A, Eftekhari Yazdi G, **Tsui JI**, Strick L, Linas BP. Hepatitis C testing and patient characteristics in Washington state's prisons between 2012 and 2016. *Am J Prev Med.* 2018 Nov 12. PMCID: PMC6312183.
46. Frost MC, Matson TE, **Tsui JI**, Williams EC. Influence of comorbid drug use disorder on receipt of evidence-based treatment for alcohol use disorder among VA patients with alcohol use disorder and hepatitis C and/or HIV. *Drug Alcohol Depend.* 2018 Oct 30;194:288-295. PMCID: PMC6312483.
47. James JR, Gordon LM, Klein JW, Merrill JO, **Tsui JI**. Interest in prescribing buprenorphine among resident and attending physicians at an urban teaching clinic. *Subst Abus.* 2018 Mar 26;1-3. PMID: 29578857.
48. Klein JW, Peacock S, **Tsui JI**, O'Neill SF, DesRoches CM, Elmore JG. Perceptions of primary care notes by patients with mental health diagnoses. *Ann Fam Med.* 2018 Jul;16(4):343-345. PMCID: PMC6037508.
49. Gnatienco, N, Wagman JA, Cheng MD, Bazzi A, Raj A, Blokhina E, Toussova O, Forman LS, Lioznov D, Briden C, Sullivan M, Bryant K, Samet JH, **Tsui JI**. Serodiscordant partnerships and opportunities for pre-exposure prophylaxis among partners of women and men living with HIV in St. Petersburg, Russia. *PLoS One.* 2018 Nov 16;13(11):e0207402. PMCID: PMC6239322.
50. **Tsui JI**, Miller CM, Scott JD, Corcorran MA, Dombrowski JC, Glick SN. Hepatitis C continuum of care and utilization of healthcare and harm reduction services among persons who inject drugs in Seattle. *Drug Alcohol Depend.* 2019 Feb 1;195:114-120. Epub 2018 Dec 26. PMCID: PMC6440747.*
51. Colasanti J, Lira MC, Cheng DM, Liebschutz JM, **Tsui JI**, Forman LS, Sullivan M, Walley AY, Briden C, Root C, Podolsky M. Chronic opioid therapy in people living with Human Immunodeficiency Virus: patients' perspectives on risks, monitoring, and guidelines. *Clin Infect Dis.* 2019 Jan 7;68(2):291-297. PMCID: PMC6594413.
52. **Tsui JI**, Walley AY, Cheng DM, Lira MC, Liebschutz JM, Forman LS, Sullivan MM, Colasanti J, Root C, O'Connor K, Shanahan CW, Briden CL, del Rio C, Samet JH. Provider opioid prescribing practices and the belief that opioids keep people living with HIV engaged in care: a cross-sectional study. *AIDS Care.* 2019 Jan 11:1-5. PMCID: PMC6625838.
53. Geddes L, Iversen J, Wand H, Esmaeili A, **Tsui J**, Hellard M, Dore G, Grebely J, Dietze P, Bruneau J, Prins M, Morris MD, Shoukry NH, Lloyd AR, Kim AY, Lauer G, Cox AL, Page K, Maher L; InC3 Collaborative. Sex discrepancies in the protective effect of opioid agonist therapy on incident hepatitis C infection. *Clin Infect Dis.* 2019 Feb 28. PMCID: PMC6912156.
54. Godersky ME, Saxon AJ, Merrill JO, Samet JH, Simoni JM, **Tsui JI**. Provider and patient perspectives on barriers to buprenorphine adherence and the acceptability of video directly observed therapy to enhance adherence. *Addict Sci Clin Pract.* 2019 Mar 13;14(1):11. doi: 10.1186/s13722-019-0139-3. PMCID: PMC6417248.*

55. Lira MC, **Tsui JI**, Liebschutz JM, et al. Study protocol for the targeting effective analgesia in clinics for HIV (TEACH) study - a cluster randomized controlled trial and parallel cohort to increase guideline concordant care for long-term opioid therapy among people living with HIV. *HIV Res Clin Pract.* 2019 Apr;20(2):48-63. PMCID: PMC6693587.
56. Payne BE, Klein JW, Simon CB, James, JR, Jackson SL, Merrill JO, Zhuang R, and **Tsui JI**. Effect of lowering initiation thresholds in a primary care-based buprenorphine treatment program. *Drug Alcohol Depend.* 2019 May 1;200:71-77. PMID: 31103879.
57. Price CJ, Merrill JO, McCarty RL, Pike KC, **Tsui JI**. A Pilot Study of Mindful Body Awareness Training as an Adjunct to Office-Based Medication Treatment of Opioid Use Disorder. *J Subst Abuse Treat.* 2019 May 23. PMCID: PMC6874727.
58. Merlin JS, Samet JH, Cheng DM, Lira MC, **Tsui JI**, Forman LS, Colasanti J, Walley AY, Del Rio C, Liebschutz JM. Marijuana Use and Its Associations With Pain, Opioid Dose, and HIV Viral Suppression Among Persons Living With HIV on Chronic Opioid Therapy. *J Acquir Immune Defic Syndr.* 2019 Oct 1;82(2):195-201. PMCID: PMC6746234.
59. Litwin AH, Jost J, Wagner K, Heo M, Karasz A, Feinberg J, Kim AY, Lum PJ, Mehta SH, Taylor LE, **Tsui JI**, Pericot-Valverde I, Page K; HERO Study Group. Rationale and design of a randomized pragmatic trial of patient-centered models of hepatitis C treatment for people who inject drugs: The HERO study. *Contemp Clin Trials.* 2019 Oct 24;105859. PMCID: PMC7261375.
60. Banta-Green CJ, Floyd AS, Vick K, Arthur J, Hoeft TJ, **Tsui JI**. Opioid Use Disorder Treatment Decision Making and Care Navigation Upon Release From Prison: A Feasibility Study. *Subst Abuse Rehabil.* 2019 Oct 22;10:57-67. PMCID: PMC6815213.
61. **Tsui JI**, Mayfield J, Speaker EC, Yakup S, Ries R, Funai H, Leroux BG, Merrill JO. Association between methamphetamine use and retention among patients with opioid use disorders treated with buprenorphine. *J Subst Abuse Treat.* 2019 Nov 18. PMID: 31810594.*
62. Banta-Green CJ, Williams JR, Sears JM, Floyd AS, **Tsui JI**, Hoeft TJ. Impact of a jail-based treatment decision-making intervention on post-release initiation of medications for opioid use disorder. *Drug Alcohol Depend.* 2019 Dec 11;207:107799.[Epub ahead of print]. PMID: 31865058.
63. Godersky ME, Klein JW, Merrill JO, Blalock KL, Saxon AJ, Samet JH, **Tsui JI**. Acceptability and Feasibility of a Mobile Health Application for Video Directly Observed Therapy of Buprenorphine for Opioid Use Disorders in an Office-based Setting. *J Addict Med.* 2020 Jan;14(4):319-325. PMID: 31972762; PMCID: PMC7358111.*
64. Peavy KM, Darnton J, Grekin P, Russo M, Green CJB, Merrill JO, Fotinos C, Woolworth S, Soth S, **Tsui JI**. Rapid Implementation of Service Delivery Changes to Mitigate COVID-19 and Maintain Access to Methadone Among Persons with and at High-Risk for HIV in an Opioid Treatment Program. *AIDS Behav.* 2020 Apr 28. doi: 10.1007/s10461-020-02887-1. PMID: 32347404; PMCID: PMC7186943.
65. Serota DP, Capozzi C, Lodi S, Colasanti JA, Forman LS, **Tsui JI**, Walley AY, Lira MC, Samet J, Rio CD, Merlin JS. Predictors of pain-related functional impairment among people living with HIV on long-term opioid therapy. *AIDS Care.* 2020 Apr 3;1-9. PMID: 32242463; PMCID: PMC7541400
66. Donroe JH, Bhatraju EP, **Tsui JI**, Edelman EJ. Identification and Management of Opioid Use Disorder in Primary Care: an Update. *Curr Psychiatry Rep.* 2020 Apr 13;22(5):23. doi: 10.1007/s11920-020-01149-0. PMID: 32285215
67. Samet JH, **Tsui JI**, Cheng DM, Liebschutz JM, Lira MC, Walley AY, Colasanti JA, Forman LS, Root C, Shanahan CW, Sullivan MM, Briden CL, Abrams C, Harris C, Outlaw K, Armstrong WS, Del Rio C. Improving the Delivery of Chronic Opioid Therapy Among People Living With Human Immunodeficiency Virus: A Cluster Randomized Clinical Trial. *Clin Infect Dis.* 2021 Oct 5;73(7):e2052-e2058. doi: 10.1093/cid/ciaa1025. PMID: 32697847; PMCID: PMC8492355.
68. Schramm ZA, Leroux BG, Radick AC, Ventura AS, Klein JW, Samet JH, Saxon A, Kim TW, **Tsui JI**. Video directly observed therapy intervention using a mobile health application among opioid use disorder patients receiving office-based buprenorphine treatment – protocol for a pilot randomized controlled trial. *Addict Sci Clin Pract.* 2020 Jul 31;15(1):30. doi: 10.1186/s13722-020-00203-9. PMID: 32736660, PMCID: PMC7393902
69. Frost MC, Ioannou GN, **Tsui JI**, Edelman EJ, Weiner BJ, Fletcher OV, Williams EC. Practice Facilitation to Implement Alcohol-Related Care in Veterans Health Administration Liver Clinics: A Study Protocol. *Implement Sci Commun.* 2020;1(1):68. doi: 10.1186/s43058-020-00062-0. Epub 2020 Jul 31. PMID: 32835226, PMCID: PMC7393339

70. Chawarski M, Hawk K, Edelman EJ, O'Connor P, Owens P, Martel S, Coupet E, Whiteside L, **Tsui JI**, Rothman R, Cowan E, Richardson L, Lyons MS, Fiellin DA, D'Onofrio G. Use of Amphetamine-Type Stimulants Among Emergency Department Patients With Untreated Opioid Use Disorder. *Ann. Emerg. Med.* 2020 Aug 8. doi: 10.1016/j.annemergmed.2020.06.046. PMID: 32782084.
71. Piske M, Thomson T, Krebs E, Hongdilokkul N, Bruneau J, Greenland S, Gustafson P, Karim ME, McCandless LC, Maclure M, Platt RW, Siebert S, Socias ME, **Tsui JI**, Wood E, Nosyk B. Comparative effectiveness of buprenorphine-naloxone versus methadone for treatment of opioid use disorder: a population-based observational study protocol in British Columbia, Canada. *BMJ Open.* 2020;10:e036102. doi: 10.1136/bmjopen-2019-036102. PMID: 32912944, PMCID: PMC7482450
72. Wagman JA, Wynn A, Matsuzaki M, Gnatenko N, Metsch LR, Del Rio C, Feaster DJ, Nance RM, Whitney BM, Delaney JAC, Kahana SY, Crane HM, Chandler RK, Elliott JC, Altice F, Lucas GM, Mehta SH, Hirsch-Moverman Y, El-Sadr WM, Vu Q, Thanh BN, Springer SA, **Tsui JI**, Samet JH. Hazardous alcohol use, antiretroviral therapy receipt and viral suppression in people living with HIV who inject drugs in the U.S., India, Russia and Vietnam. *AIDS.* 2020 Oct 8. doi: 10.1097/QAD.0000000000002716. Online ahead of print. PMID: 33048870
73. Bhatraju EP, Ludwig-Barron N, Takagi-Stewart J, Sandhu HK, Klein JW, **Tsui JI**. Successful engagement in buprenorphine treatment among hospitalized patients with opioid use disorder and trauma. *Drug Alcohol Depend.* 2020 Oct 1;215:108253. doi: 10.1016/j.drugalcdep.2020.108253. Epub 2020 Aug 27. PMID: 32890919, PMCID: PMC7531192*
74. Hatch-Maillette M, Peavy KM, **Tsui JI**, Banta-Green CJ, Woolworth S, Grekin P. "Re-thinking patient stability for methadone in opioid treatment programs during a global pandemic: Provider perspectives" *Journal of Substance Abuse Treatment*, 2020 Dec 5. doi: 10.1016/j.jsat.2020.108223. PMID: 33342667
75. Corcorran MA, **Tsui JI**, Scott JD, Dombrowski JC, Glick SN. Age and gender-specific hepatitis C continuum of care and predictors of direct acting antiviral treatment among persons who inject drugs in Seattle, Washington. *Drug Alcohol Depend.* 2021 Jan 1;220:108525. doi: 10.1016/j.drugalcdep.2021.108525. Epub ahead of print. PMID: 33461152.
76. Crane HM, Nance RM, Whitney BM, Ruderman S, **Tsui JI**, Chander G, McCaul ME, Lau B, Mayer KH, Batey DS, Safren SA, Moore RD, Eron JJ, Napravnik S, Mathews WC, Fredericksen RJ, Hahn AW, Mugavero MJ, Lober WB, Saag MS, Kitahata MM, Delaney JAC. Drug and alcohol use among people living with HIV in care in the United States by geographic region. *AIDS Care.* 2021 Jan 23;1-8. doi: 10.1080/09540121.2021.1874274. Epub ahead of print. PMID: 33486978.
77. **Tsui JI**, Lapham G, Boudreau DM, Johnson E, Binswanger IA, Cunningham CO, Thakral M, Arnsten JH, Saxon AJ, Merrill JO, Samet JH, Bart G, Campbell CI, Bradley KA. Opioid use disorder among persons with Hepatitis C and HIV: Data from 6 health systems. *Journal of General Internal Medicine*, 2021 Feb 10. doi: 10.1007/s11606-020-06389-7. Epub ahead of print. PMID: 33569735.*
78. Kimmel SD, Walley AY, Lodi S, Forman LS, Liebschutz JM, Lira MC, del Rio C, Samet JH, **Tsui JI**. Naloxone Receipt and Overdose Prevention Care Among People with HIV on Chronic Opioid Therapy. *AIDS*, (London, England). 2021 Mar;35(4):697-700. doi: 10.1097/qad.0000000000002803. PMID: 33587441.
79. Campbell CI, Saxon AJ, Boudreau D, Wartko PD, Bobb JF, Lee AK, Matthews AG, McCormack J, Liu DS, Addis M, Altschuler A, Samet JH, LaBelle CT, Arnsten J, Caldeiro RM, Borst DT, Stotts AL, Braciszewski JM, Szapocznik J, Bart G, Schwartz RP, McNeely J, Liebschutz JH, **Tsui JI**, Merrill JO, Glass JE, Lapham GT, Murphy SM, Weinstein ZM, Yarborough BJH, Bradley KA. Primary Care Opioid Use Disorders treatment (PROUD) trial protocol A pragmatic, cluster-randomized implementation trial in primary care for opioid use disorder treatment. *Addiction Science and Clinical Practice*, 2021 Jan 31;16(1):9. doi: 10.1186/s13722-021-00218-w. PMID: 33517894, PMCID: PMC7849121.
80. Ganguly, A, Lira MC, Lodi, S, Forman, LS, Colasanti, J, Williams, EC, Liebschutz, JM, Del Rio, C, Samet, JH, **Tsui, JI**. Race and Satisfaction with Pain Management among Patients with HIV Receiving Long-Term Opioid Therapy. *Drug Alcohol Depend.* 2021 May 1;222:108662. doi: 10.1016/j.drugalcdep.2021.108662. Epub 2021 Mar 18. PMID: 33775447, PMCID: PMC8005420.
81. Bhatraju E, Liebschutz JM, Lodi S, Forman LS, Lira MC, Kim TW, Colasanti J, del Rio C, Samet JH, **Tsui JI**. (2021) Post-Traumatic Stress Disorder and Risky Opioid Use among Persons Living with HIV and Chronic Pain, *AIDS Care*, 2021 Feb 4;1-8. doi: 10.1080/09540121.2021.1876838. PMID: 33535800
82. Bendiks S, Cheng DM, Blokhina E, Vetrova M, Verbitskaya E, Gnatenko N, Bryant K, Krupitsky E, Samet JH, **Tsui JI**. Pilot study of tolerability and safety of opioid receptor antagonists as novel therapies for chronic pain

- among persons living with HIV with past year heavy drinking: a randomized controlled trial. 2021. *AIDS Care*. 2021 Mar 7;1-10. doi: 10.1080/09540121.2021.1896663. PMID: 33682527
83. Corcorran MA, Ludwig-Baron N, Cheng DM, Lioznov D, Gnatienco N, Patts G, So-Armah K, Blokhina E, Bendiks S, Krupitsky E, Samet JH, **Tsui JI**. The Hepatitis C Continuum of Care among HIV-positive Persons with Heavy Alcohol Use in St. Petersburg, Russia. *AIDS and Behavior*. 2021 Mar 17. doi: 10.1007/s10461-021-03214-y. PMID: 33730255.
84. Merlin JS, Hamm M, De Abril Cameron F, Baker V, Brown DA, Cherry CL, Edelemen EJ, Evangeli M, Harding R, Josh J, Kemp HI, Lichius C, Madden VJ, Nkhoma K, O'Brien KK, Parker R, Rice A, Robinson-Papp J, Sabin CA, Slawek D, Scott W, **Tsui JI**, Uebelacker LA, Wadley AL, Goodin BR. The Global Task Force for Chronic Pain in People with HIV (PWH): Developing a research agenda in an emerging field. *AIDS Care*. 2021 Mar 22;1-9. doi: 10.1080/09540121.2021.1902936. Online ahead of print. PMID: 33745403
85. Ngo B, Liebschutz J, Cheng DM, Colasanti J, Merlin JS, Armstrong W, Forman L, Samet JH, DelRio C, **Tsui JI**. Hazardous Alcohol Use is Associated with Greater Pain Interference and Prescription Opioid Misuse Among Persons Living with HIV and Chronic Pain. *BMC Public Health*. 2021 Mar 22;21(1):564. doi: 10.1186/s12889-021-10566-6. PMID: 33752634
86. Ngo BV, James JR, Blalock KL, Jackson SL, Chew LD, **Tsui JI**. Hepatitis C treatment outcomes among patients treated in co-located primary care and addiction treatment settings. *Journal of Substance Abuse Treatment*. Volume 131, 2021 Apr 29;131:108438. doi: 10.1016/j.jsat.2021.108438. Epub ahead of print. PMID: 34098298.
87. Poorman E, Glick SN, Hiser JKD, Bhatraju EP, **Tsui JI**. Increased Utilization of Buprenorphine and Methadone in 2018 Compared to 2015 among Seattle-area Persons Who Inject Drugs. *Journal of Substance Abuse Treatment*. Volume 129, 2021 Mar 19;129:108375. doi: 10.1016/j.jsat.2021.108375. Epub ahead of print. PMID: 34080546.
88. Chen J, Cabudoll MJ, Williams EC, Merrill JO, **Tsui JI**, Klein JW. Perspectives on Electronic Portal Use Among Patients with Opioid Use Disorder. *Journal of Substance Abuse Treatment*. Volume 126, 2021 Jul;126:108463. doi: 10.1016/j.jsat.2021.108463. Epub 2021 May 7. PMID: 34116814.
89. Gnatienco N, Calver K, Sullivan M, Forman LS, Heeren T, Blokhina E, Emenyonu N, Ventura AS, **Tsui JI**, Muyindike WR, Fatch R, Ngabirano C, Briden C, Bryant K, Bazzi AR, Hahn JA. Heavy Alcohol Use Among Women and Men Living With HIV in Uganda, Russia, and the United States. *J Stud Alcohol Drugs*. 2021 Jul;82(4):486-492. PMID: 34343080.
90. James JR, Marolf M, Klein JW, Blalock KL, Merrill JO, **Tsui JI**. Staff Attitudes toward Buprenorphine before and after Implementation of an Office-Based Opioid Treatment Program in an Urban Teaching Clinic. *Subst Use Misuse*. 2021;56(11):1569-1575. doi: 10.1080/10826084.2021.1928206. Epub 2021 Jul 20. PMID: 34282999.
91. **Tsui JI**, Leroux BG, Radick AC, Schramm ZA, Blalock K, Labelle C, Heerema M, Klein JW, Merrill JO, Saxon AJ, Samet JH, Kim TW. Video directly observed therapy for patients receiving office-based buprenorphine - A pilot randomized controlled trial. *Drug Alcohol Depend*. 2021 Jul 28;227:108917. doi: 10.1016/j.drugalcdep.2021.108917. Epub ahead of print. PMID: 34399136.
92. **Tsui JI**, Barry MP, Austin EJ, Sweek EW, Tung E, Hansen RN, Ninburg M, Scott JD, Glick SN, Williams EC. 'Treat my whole person, not just my condition': qualitative explorations of hepatitis C care delivery preferences among people who inject drugs. *Addict Sci Clin Pract*. 2021 Aug 12;16(1):52. doi: 10.1186/s13722-021-00260-8. PMID: 34384494; PMCID: PMC8358259.
93. Joudrey PJ, Bart G, Brooner RK, Brown L, Dickson-Gomez J, Gordon A, Kawasaki SS, Liebschutz JM, Nunes E, McCarty D, Schwartz RP, Szapocnik J, Trivedi M, **Tsui JI**, Williams A, Wu LT, Fiellin DA. Research priorities for expanding access to methadone treatment for opioid use disorder in the United States: A National Institute on Drug Abuse Clinical Trials Network Task Force Report. *Substance Abuse*. 2021; 42(3): 245-254. PMID: 34606426, DOI: 10.1080/0897077.2021.1975344
94. Frost MC, Lampert H, **Tsui JI**, Iles-Shih MD, Williams EC. The impact of methamphetamine/amphetamine use on receipt and outcomes of medications for opioid use disorder: A systematic review. *Addict Sci Clin Pract*. 2021 Oct 11;16(1):62. doi: 10.1186/s13722-021-00266-2. PMID: 34635170, PMCID: PMC8504567. Free PMC article.
95. Bhatraju EP, Klein JW, Hall AN, Chen DR, Iles-Shih M, **Tsui JI**, Merrill JO. Low Dose Buprenorphine Induction With Full Agonist Overlap in Hospitalized Patients With Opioid Use Disorder: A Retrospective

- Cohort Study. *J Addict Med.* 2021 Dec 23. doi: 10.1097/ADM.0000000000000947. Online ahead of print. PMID: 34954743.
96. Austin EL, **Tsui JI**, Barry MP, Tung E, Glick SN, Ninburg M, Williams EC. Health care-seeking experiences for people who inject drugs with hepatitis C: Qualitative explorations of stigma. *J Subst Abuse Treat.* 2021 Dec 7:108684. doi: 10.1016/j.jsat.2021.108684. Online ahead of print. PMID: 34911656.
97. Colasanti JA, del Rio C, Cheng D, Liebschutz JM, Lira MC, **Tsui JI**, Walley AY, Forman L, Root C, Shanahan C, Briden CL, Abrams C, Harris C, Outlaw K, Armstrong W, Samet JH. A Collaborative Care Intervention to Improve Opioid Prescribing Among Providers Caring for Persons with HIV: Impact on Satisfaction, Confidence, and Trust. *Drug Alcohol Depend.* 2021 Dec 29;231:109250. doi: 10.1016/j.drugalcdep.2021.109250. Online ahead of print. PMID: 34998255.
98. Lyons MS, Chawarski MC, Rothman R, Whiteside L, Cowan E, Richardson LD, Hawk K, **Tsui JI**, Schwartz RP, O'Connor P, D'Onofrio G, Fiellin DA, Edelman EJ. Missed Opportunities for HIV and Hepatitis C Screening Among Emergency Department Patients With Untreated Opioid Use Disorder. *J Addict Med.* 2022 Sep 28. doi: 10.1097/ADM.0000000000001074. Epub ahead of print. PMID: 36170184.
99. Luu B, Ruderman S, Nance R, Delaney JAC, Ma J, Hahn A, Heckbert SR, Budoff MJ, Crothers K, Mathews WC, Christopolous K, Hunt PW, Eron J, Moore R, Keruly J, Lober WB, Burkholder GA, Willig A, Chander G, McCaul ME, Cropsey K, O'Cleirigh C, Peter I, Feinstein M, **Tsui JI**, Lindstroem S, Saag M, Kitahata MM, Crane HM, Drumright LN, Whitney BM. Tobacco smoking and binge alcohol use are associated with incident venous thromboembolism in an HIV cohort. *HIV Med.* 2022 Mar 28. doi: 10.1111/hiv.13309. Epub ahead of print. PMID: 35343038.
100. Braciszewski JM, Idu AE, Yarborough BJH, Stumbo SP, Bobb JF, Bradley KA, Rossom RC, Murphy MT, Binswanger IA, Campbell CI, Glass JE, Matson TE, Lapham GT, Loree AM, Barbosa-Leiker C, Hatch MA, **Tsui JI**, Arnsten JH, Stotts A, Horigian V, Hutcheson R, Bart G, Saxon AJ, Thakral M, Ling Grant D, Pflugeisen CM, Usaga I, Madziwa LT, Silva A, Boudreau DM. Sex Differences in Comorbid Mental and Substance Use Disorders Among Primary Care Patients With Opioid Use Disorder. *Psychiatr Serv.* 2022 Jun 16:appips202100665. doi: 10.1176/appi.ps.202100665. Epub ahead of print. PMID: 35707859.
101. **Tsui JI**. Stimulant Prescription Medications Among Persons Receiving Buprenorphine for Opioid Use Disorder With Prior Drug-Related Poisoning-Evidence of Net-Sum Gain. *JAMA Netw Open.* 2022 May 2;5(5):e2211641. doi: 10.1001/jamanetworkopen.2022.11641. PMID: 35544141.
102. **Tsui JI**, Campbell ANC, Pavlicova M, Choo TH, Lee JD, Cook RR, Shulman M, Nunes EV, Rotrosen J. Methamphetamine/amphetamine use over time among persons with opioid use disorders treated with buprenorphine/naloxone versus extended-release naltrexone. *Drug Alcohol Depend.* 2022 Jul 1;236:109469. doi: 10.1016/j.drugalcdep.2022.109469. Epub 2022 Apr 21. PMID: 35605529; PMCID: PMC10796081.
103. Eastment MC, Gupta A, James J, Richardson BA, Pinder L, Kim HN, Wald A, **Tsui JI**. Cervical cancer screening, abnormal results, and follow-up in women with substance use-related diagnoses. *Subst Abuse.* 2022;43(1):925-931. doi: 10.1080/08897077.2021.2010257. PMID: 35289732.
104. Owens MD, Ioannou GN, **Tsui JI**, Edelman EJ, Greene PA, Williams EC. Receipt of alcohol-related care among patients with HCV and unhealthy alcohol use. *Drug Alcohol Depend.* 2018 Jul 1;188:79-85. doi: 10.1016/j.drugalcdep.2018.03.047. Epub 2018 May 8. PMID: 29754030; PMCID: PMC5999587.
105. Levander XA, Foot CA, Magnusson SL, Cook RR, Ezell JM, Feinberg J, Go VF, Lancaster KE, Salisbury-Afshar E, Smith GS, Westergaard RP, Young AM, **Tsui JI**, Korthuis PT. Contraception and Healthcare Utilization by Reproductive-Age Women Who Use Drugs in Rural Communities: a Cross-Sectional Survey. *J Gen Intern Med.* 2022 Jun 15. doi: 10.1007/s11606-022-07558-6. Epub ahead of print. PMID: 35731368.
106. Frost MC, Richards JE, Blosnich JR, Hawkins EJ, **Tsui JI**, Edelman EJ, Williams EC. Association between clinically recognized suicidality and subsequent initiation or continuation of medications for opioid use disorder. *Drug Alcohol Depend.* 2022 Jun 3;237:109521. doi: 10.1016/j.drugalcdep.2022.109521. Epub ahead of print. PMID: 35716644.
107. Jenkins RA, Whitney BM, Nance RM, Allen TM, Cooper HLF, Feinberg J, Fredericksen R, Friedmann PD, Go VF, Jenkins WD, Korthuis PT, Miller WC, Pho MT, Rudolph AE, Seal DW, Smith GS, Stopka TJ, Westergaard RP, Young AM, Zule WA, Delaney JAC, **Tsui JI**, Crane HM; Rural Opioid Initiative. The Rural Opioid Initiative Consortium description: providing evidence to Understand the Fourth Wave of the Opioid Crisis. *Addict Sci Clin Pract.* 2022 Jul 26;17(1):38. doi: 10.1186/s13722-022-00322-5. PMID: 35883197; PMCID: PMC9321271.

108. Jack HE, Denisiuk ED, Collins BA, Stephens D, Blalock KL, Klein JW, Bhatraju EP, Merrill JO, Hallgren KA, **Tsui JI**. Peer providers and linkage with buprenorphine care after hospitalization: A retrospective cohort study. *Subst Abuse*. 2022 Dec;43(1):1308-1316. doi: 10.1080/08897077.2022.2095078. PMID: 35896006.
109. Litwin AH, Lum PJ, Taylor LE, Mehta SH, **Tsui JI**, Feinberg J, Kim AY, Norton BL, Heo M, Arnsten J, Meissner P, Karasz A, McKee MD, Ward JW, Johnson N, Pericot-Valverde I, Agyemang L, Stein ES, Thomas A, Borsuk C, Blalock KL, Wilkinson S, Wagner K, Roche J, Murray-Kreza C, Anderson J, Jacobsohn V, Luetkemeyer AF, Falade-Nwulia O, Page K; HERO Study Group. Patient-centred models of hepatitis C treatment for people who inject drugs: a multicentre, pragmatic randomised trial. *Lancet Gastroenterol Hepatol*. 2022 Dec;7(12):1112-1127. doi: 10.1016/S2468-1253(22)00275-8. PMID: 36370741.
110. Williams EC, Frost MC, Lodi S, Forman LS, Lira MC, **Tsui JI**, Lunze K, Kim T, Liebschutz JM, Rio CD, Samet JH. Influence of patient trust in provider and health literacy on receipt of guideline-concordant chronic opioid therapy in HIV care settings. *J Opioid Manag*. 2023 Sep-Oct;19(5):385-393. doi: 10.5055/jom.0812. PMID: 37968972.
111. Korthuis PT, Cook RR, Foot CA, Leichtling G, **Tsui JI**, Stopka TJ, Leahy J, Jenkins WD, Baker R, Chan B, Crane HM, Cooper HL, Feinberg J, Zule WA, Go VF, Estadt AT, Nance RM, Smith GS, Westergaard RP, Van Ham B, Brown R, Young AM. Association of Methamphetamine and Opioid Use With Nonfatal Overdose in Rural Communities. *JAMA Netw Open*. 2022 Aug 1;5(8):e2226544. doi: 10.1001/jamanetworkopen.2022.26544. PMID: 35969400.
112. Nolan S, Fairgrieve C, Dong H, Garrod E, van Heukelom H, Parappilly BP, McLean M, **Tsui JI**, Samet JH. A Hospital-based Managed Alcohol Program in a Canadian Setting. *J Addict Med*. 2022 Sep 23. doi: 10.1097/ADM.0000000000001080. Epub ahead of print. PMID: 36149000.
113. Hallgren KA, Darnton J, Soth S, Blalock KL, Michaels A, Grekin P, Saxon AJ, Woolworth S, **Tsui JI**. Acceptability, feasibility, and outcomes of a clinical pilot program for video observation of methadone take-home dosing during the COVID-19 pandemic. *J Subst Abuse Treat*. 2022 Dec;143:108896. doi: 10.1016/j.jsat.2022.108896. Epub 2022 Oct 4. PMID: 36215911; PMCID: PMC9531364.
114. Radick AC, James J, Leroux BG, Kim TW, Saxon AJ, Samet JH, **Tsui JI**. Use of Video Directly Observed Therapy and Characteristics Associated With Use Among Patients Treated With Buprenorphine in an Office-based Setting. *J Addict Med*. 2023 May-Jun 01;17(3):300-304. doi: 10.1097/ADM.0000000000001103. Epub 2022 Oct 25. PMID: 37267172; PMCID: PMC10123169.
115. Barry MP, Austin EJ, Bhatraju EP, Glick SN, Stekler JD, Tung EL, Hansen RN, Williams EC, Gojic AJ, Pickering EI, **Tsui JI**. Qualitative inquiry into perceptions of HIV pre-exposure prophylaxis among people who inject drugs living with hepatitis C in Seattle, WA, USA. *Harm Reduct J*. 2022 Nov 1;19(1):121. doi: 10.1186/s12954-022-00706-5. PMID: 36320005; PMCID: PMC9628120.
116. Austin EJ, Gojic AJ, Bhatraju EP, Pierce KA, Pickering EI, Tung EL, Scott JD, Hansen RN, Glick SN, Stekler JD, Connolly NC, Villafuerte S, McPadden M, Deutsch S, Ninburg M, Kubiniec R, Williams EC, **Tsui JI**. Barriers and facilitators to implementing a Pharmacist, Physician, and Patient Navigator-Collaborative Care Model (PPP-CCM) to treat hepatitis C among people who inject drugs. *Int J Drug Policy*. 2022 Dec 13;111:103924. doi: 10.1016/j.drugpo.2022.103924. Epub ahead of print. PMID: 36521197.
117. Button D, Levander XA, Cook RR, Miller WC, Salisbury-Afshar EM, **Tsui JI**, Ibragimov U, Jenkins WD, Westergaard RP, Korthuis PT. Substance use disorder treatment and technology access among people who use drugs in rural areas of the United States: A cross-sectional survey. *J Rural Health*. 2022 Dec 27. doi: 10.1111/jrh.12737. Epub ahead of print. PMID: 36575145.
118. Kratina-Hathaway Z, Radick AC, Leroux BG, Blalock K, Kim TW, Darnton J, Saxon AJ, Samet JH, Tsui JI. Methamphetamine use and illicit opioid use during buprenorphine treatment. *J Subst Use Addict Treat*. 2023 Aug;151:208934. doi: 10.1016/j.josat.2022.208934. Epub 2023 Jan 6. PMID: 37811395; PMCID: PMC10554569.
119. Karasz A, Merchant K, Arnsten J, Feinberg J, Kim AY, Lum PJ, McKee MD, Mehta SH, Meissner P, Norton BL, Page K, Pericot-Valverde I, Singh R, Stein E, Taylor LE, **Tsui JI**, Wagner K, Litwin A. A Video-Observed Treatment Strategy to Improve Adherence to Treatment Among Persons Who Inject Drugs Infected With Hepatitis C Virus: Qualitative Study of Stakeholder Perceptions and Experiences. *J Med Internet Res*. 2023 Jun 2;25:e38176. doi: 10.2196/38176. PMID: 37266986.
120. **Tsui JI**, Stephens D, Collins B, Denisiuk E, Hallgren KA, Blalock KL, Klein JW, Jack HE, Merrill JO. Co-use of Methamphetamine Is Associated With Lower Rates of Linkage to Outpatient Treatment for Hospitalized

- Patients Who Initiate Buprenorphine. *J Addict Med*. 2023 Jan 17. doi: 10.1097/ADM.0000000000001129. Epub ahead of print. PMID: 37579119.
121. Cook RR, Foot C, Arah OA, Humphreys K, Rudolph KE, Luo SX, **Tsui JI**, Levander XA, Korthuis PT. Estimating the impact of stimulant use on initiation of buprenorphine and extended-release naltrexone in two clinical trials and real-world populations. *Addict Sci Clin Pract*. 2023 Feb 14;18(1):11. doi: 10.1186/s13722-023-00364-3. PMID: 36788634; PMCID: PMC9930351.
122. Karasz A, Merchant K, Singh R, Thomas A, Borsuk C, McKee D, Duryea P, Kim AY, Mehta S, Norton BL, Page K, Pericot-Valverde I, Sedillo S, Stein ES, Taylor LE, **Tsui J**, Litwin A. The experience of re-infection among people who inject drugs successfully treated for hepatitis C. *J Subst Use Addict Treat*. 2023 Mar;146:208937. doi: 10.1016/j.josat.2022.208937. Epub 2023 Jan 6. PMID: 36880897.
123. Darnton JB, Bhatraju EP, Beima-Sofie K, Michaels A, Hallgren KA, Soth S, Grekin P, Woolworth S, **Tsui JI**. "Sign Me Up": a qualitative study of video observed therapy (VOT) for patients receiving expedited methadone take-homes during the COVID-19 pandemic. *Addict Sci Clin Pract*. 2023 Mar 29;18(1):21. doi: 10.1186/s13722-023-00372-3. PMID: 36991506; PMCID: PMC10052285.
124. D'Onofrio G, Edelman EJ, Hawk KF, Chawarski MC, Pantaloni MV, Owens PH, Martel SH, Rothman R, Saheed M, Schwartz RP, Cowan E, Richardson L, Salsitz E, Lyons MS, Freiermuth C, Wilder C, Whiteside L, **Tsui JI**, Klein JW, Coupet E, O'Connor PG, Matthews AG, Murphy SM, Huntley K, Fiellin DA. Implementation Facilitation to Promote Emergency Department-Initiated Buprenorphine for Opioid Use Disorder. *JAMA Netw Open*. 2023 Apr 3;6(4):e235439. doi: 10.1001/jamanetworkopen.2023.5439. PMID: 37017967; PMCID: PMC10077107.
125. **Tsui JI**, Lum PJ, Taylor LE, Mehta SH, Feinberg J, Kim AY, Norton BL, Niu J, Heo M, Arnsten J, Pericot-Valverde I, Thomas A, Blalock KL, Radick A, Murray-Krezan C, Page K, Litwin AH; HERO Study Group. Injecting practices during and after hepatitis C treatment and associations with not achieving cure among persons who inject drugs. *Drug Alcohol Depend*. 2023 Apr 17;247:109878. doi: 10.1016/j.drugalcdep.2023.109878. Epub ahead of print. PMID: 37150144.
126. James JR, **Tsui JI**. Training Providers of People Who Use Drugs to Offer Hepatitis C Treatment: A Washington State Initiative. *Subst Abuse*. 2023 Jan-Apr;44(1):86-90. doi: 10.1177/08897077231167047. Epub 2023 Apr 26. PMID: 37226904.
127. Sue KL, Chawarski M, Curry L, McNeil R, Coupet E Jr, Schwartz RP, Wilder C, **Tsui JI**, Hawk KF, D'Onofrio G, O'Connor PG, Fiellin DA, Edelman EJ. Perspectives of Clinicians and Staff at Community-Based Opioid Use Disorder Treatment Settings on Linkages With Emergency Department-Initiated Buprenorphine Programs. *JAMA Netw Open*. 2023 May 1;6(5):e2312718. doi: 10.1001/jamanetworkopen.2023.12718. PMID: 37163263.
128. Geist ML, Radick AC, **Tsui JI**, Blalock KL, Adwell A, Tamru E, Connolly NC, James JR. Timing of hepatitis C treatment initiation and retention in office-based opioid treatment with buprenorphine: a retrospective cohort study. *Addict Sci Clin Pract*. 2023 May 25;18(1):33. doi: 10.1186/s13722-023-00389-8. PMID: 37231486; PMCID: PMC10210339.
129. Bhatraju EP, Radick AC, Leroux BG, Kim TW, Samet JH, **Tsui JI**. Buprenorphine adherence and illicit opioid use among patients in treatment for opioid use disorder. *Am J Drug Alcohol Abuse*. 2023 Jun 27:1-8. doi: 10.1080/00952990.2023.2220876. Epub ahead of print. PMID: 37369019.
130. Idrisov B, Hallgren KA, Michaels A, Soth S, Darnton J, Grekin P, Woolworth S, Saxon AJ, **Tsui JI**. Workload, Usability, and Engagement with a Mobile App Supporting Video Observation of Methadone Take-Home Dosing: Usability Study. *JMIR Hum Factors*. 2023 Jul 13;10:e42654. doi: 10.2196/42654. PMID: 37440298.
131. Altwies EE, Zinsli KA, Chwastiak L, **Tsui JI**, Bhatraju EP, Ramchandani MS, Golden MR, Dombrowski JC. Substance Use and Mental Health Comorbidities and Receipt of Specialty Care Among Patients Enrolled in a Low-Barrier HIV Clinic. *AIDS Behav*. 2023 Jun 23. doi: 10.1007/s10461-023-04110-3. Epub ahead of print. PMID: 37351687.
132. **Tsui JI**, Whitney BM, Korthuis PT, Chan B, Pho MT, Jenkins WD, Young AM, Cooper HLF, Friedmann PD, Stopka TJ, de Gijzel D, Miller WC, Go VF, Westergaard R, Brown R, Seal DW, Zule WA, Feinberg J, Smith GS, Mixson LS, Fredericksen R, Crane HM, Delaney JA; Rural Opioid Initiative Consortium. Methamphetamine use and utilization of medications for opioid use disorder among rural people who use drugs. *Drug Alcohol Depend*. 2023 Aug 2;250:110911. doi: 10.1016/j.drugalcdep.2023.110911. Epub ahead of print. PMID: 37549545.
133. Wartko PD, Bobb JF, Boudreau DM, Matthews AG, McCormack J, Lee AK, Qiu H, Yu O, Hyun N, Idu AE, Campbell CI, Saxon AJ, Liu DS, Altschuler A, Samet JH, Labelle CT, Zare-Mahrjerdi A, Stotts AL,

- Braciszewski JM, Murphy MT, Dryden D, Arnsten JH, Cunningham CO, Horigian VE, Szapocznik J, Glass JE, Caldeiro RM, Phillips RC, Shea M, Bart G, Schwartz RP, McNeely J, Liebschutz JM, **Tsui JI**, Merrill JO, Lapham GT, Addis M, Bradley KA, PROUD Trial Collaborators. The PRimary Care Opioid Use Disorders treatment (PROUD) trial: a cluster-randomized implementation trial of nurse care management for opioid use disorder treatment. *JAMA Intern Med*. In press.
134. Salow K, Jack HE, Tinsley J, Banta-Green CJ, Kingston S, Iles-Shih M, **Tsui JI**, Glick S. Racial disparities in use of syringe service programs in King County, WA: a comparison of two cross-sectional surveys. *Harm Reduct J*. 2023 Sep 14;20(1):133. doi: 10.1186/s12954-023-00868-w. PMID: 37704989; PMCID: PMC10500904.
 135. Liu AW, Yang WT, Glick SN, Kim HN, Beiler AM, Lan KF, Dhanireddy S, **Tsui JI**. Stimulant Co-use Is Associated With Patient-directed Discharges in Hospitalized Patients with Opioid Use and Injection Drug Use Related Infections. *J Addict Med*. 2023 Nov-Dec 01;17(6):746-747. doi: 10.1097/ADM.0000000000001226. Epub 2023 Sep 20. PMID: 37934554.
 136. Foot C, Korthuis PT, **Tsui JI**, Luo SX, Chan B, Cook RR. Associations between stimulant use and return to illicit opioid use following initiation onto medication for opioid use disorder. *Addiction*. 2023 Sep 15. doi: 10.1111/add.16334. Epub ahead of print. PMID: 37712113.
 137. Dombrowski JC, Halliday S, **Tsui JI**, Rao D, Sherr K, Ramchandani MS, Emerson R, Fleming M, Wood T, Chwastiak L. Adaptation of the collaborative care model to integrate behavioral health care into a low-barrier HIV clinic. *Implement Res Pract*. 2023 Apr 17;4:26334895231167105. doi: 10.1177/26334895231167105. PMID: 37790178; PMCID: PMC10123894.
 138. Batchelder AW, Heo M, Foley JD, Sullivan MC, Lum P, Pericot Valverde I, Taylor LE, Mehta SH, Kim AY, Norton B, **Tsui JI**, Feinberg J, Page K, Litwin AH; HERO Study Group. Shame and stigma in association with the HCV cascade to cure among people who inject drugs. *Drug Alcohol Depend*. 2023 Oct 31;253:111013. doi: 10.1016/j.drugalcdep.2023.111013. Epub ahead of print. PMID: 37951006.
 139. **Tsui JI**, Gojic AJ, Pierce KA, Tung EL, Connolly NC, Radick AC, Hunt RR, Sandvold R, Taber K, Kubinieć RH, Scott JD, Hansen RN, Stekler JD, Austin EJ, Williams EC, Glick SN. Feasibility and outcomes of a community pharmacist led program to treat hepatitis C virus among people who inject drugs. *Drug and Alcohol Dependence Reports*, In Press.
 140. Heo M, Norton BL, Pericot-Valverde I, Mehta SH, **Tsui JI**, Taylor LE, Lum PJ, Feinberg J, Kim AY, Arnsten J, Sprecht-Walsh S, Page K, Litwin AH. Optimal hepatitis C treatment adherence patterns and sustained virologic response among people who inject drugs: The HERO study. *Journal of Hepatology*.
 141. Soyer EM, Frost MC, Fletcher OV, Ioannou GN, **Tsui JI**, Edelman EJ, Weiner BJ, Bachrach RL, Chen JA, Williams EC. Perspectives of clinical stakeholders and patients from four VA liver clinics to tailor practice facilitation for implementing evidence-based alcohol-related care. *Addict Sci Clin Pract*. 2024 Jan 10;19(1):3. doi: 10.1186/s13722-023-00429-3. PMID: 38200496.
 142. Lopes SS, Pericot-Valverde I, Arnsten J, Lum PJ, Taylor LE, Mehta SH, **Tsui JI**, Feinberg J, Kim AY, Norton BL, Page K, Murray-Krezan C, Anderson J, Moschella P, Heo M, Litwin AH. Self-reported and measured adherence to hepatitis C direct-acting antiviral therapy and sustained virologic response among people who inject drugs: The HERO study. *Int J Drug Policy*. 2023 Dec 15;123:104288. doi: 10.1016/j.drugpo.2023.104288. Epub ahead of print. PMID: 38103458.
 143. Pericot-Valverde I, Lopes SS, Nahvi S, Thrasher JF, Karasz A, Taylor LE, Mehta SH, Lum PJ, **Tsui JI**, Page K, Feinberg J, Kim AY, Norton BL, Arnsten JH, Fernandez-Artamendi S, Heo M, Litwin A; HERO Research Group. Reduction in Depressive Symptoms in People who Inject Drugs who Are Cured of Hepatitis C Virus Infection: The HERO Study. *Open Forum Infect Dis*. 2023 Oct 5;10(11):ofad498. doi: 10.1093/ofid/ofad498. PMID: 38023556; PMCID: PMC10644781.

*Top publications, as selected by personal interest and impact factors

B. COLLABORATIVE AUTHORSHIP

1. Lapham G, Boudreau DM, Johnson EA, Bobb JF, Matthews AG, McCormack J, Liu D, Samet JH, Saxon AJ, Campbell CI, Glass JE, Rossom RC, Murphy MT, Binswanger IA, Yarborough BJH, Bradley KA; **PROUD Collaborative Investigators**. Prevalence and treatment of opioid use disorders among primary care patients in

six health systems. *Drug Alcohol Depend.* 2019 Nov 15;207:107732. [Epub ahead of print]. PMID: PMC7158756.

C. MEDED PORTAL OR OTHER PEER-REVIEWED CURRICULA

N/A

D. TEXTBOOK CHAPTERS

1. **Tsui, JI.** Breast Lump Evaluation. In: Doyle JP and Martin L. Ambulatory Medicine Casebook. Lippincott and Wilkins; 2001.
2. Hasbrouk L, **Tsui JI.** Chronic Pain Syndrome. In: Branch W. Office Practice of Medicine, Fourth Edition. Harcourt Health Sciences; 2003.

E. PUBLISHED BOOKS, VIDEOS, SOFTWARE, ETC.

N/A

F. OTHER PUBLICATIONS (EDITORIAL)

1. Samet JH, **Tsui JI.** Variations in prescription opioids and related harms: a key to understanding and effective policy. *Addiction.* 2014;109(2):183-5. PMID: 24422611
2. **Tsui JI.** Stimulant Prescription Medications Among Persons Receiving Buprenorphine for Opioid Use Disorder With Prior Drug-Related Poisoning-Evidence of Net-Sum Gain. *JAMA Netw Open.* 2022 May 2;5(5):e2211641. doi: 10.1001/jamanetworkopen.2022.11641. PMID: 35544141.

G. MANUSCRIPTS SUBMITTED/ UNDER REVIEW

1. Litwin AH, **Tsui JI**, Heo M, Mehta SH, Taylor LE, Lum PJ, Feinberg J, Kim AY, Norton BL, Pericot-Valverde I, Arnsten J, Meissner P, Karasz A; Mckee MD, Ward JW, Johnson N, Agyemang L, Stein ES, Thomas A, Borsuk C, Blalock KL, Wilkinson S, Wagner L, Roche J, Murray-Krezan C, Anderson J, Jacobsohn V, Luetkemeyer AF, Falade-Nwulia O, Page K and HERO Study Group. Hepatitis C Virus Reinfection Following Successful Treatment Among People Who Inject Drugs: The HERO Study. Under Review.
2. **Tsui JI**, Rossi SL, Cheng DM, Bendicks S, Vetrova M, Blokhina E, Winter M, Gnatenko, Backonja M, Bryant K, Krupitsky E, Samet JH. Pilot RCT comparing low-dose naltrexone, gabapentin and placebo to reduce pain among people with HIV with alcohol problems. Under Review.
3. Bhatraju EP, **Tsui JI**, Moonseong H, Sivaraj LB, Radick A, Mehta SH, Lum PJ, Taylor LE, Feinberg J, Kim AY, Norton BL, Pericot-Valverde I, Page, Litwin AH. Interest in Injectable and Oral PrEP for HIV Prevention Among People Who Inject Drugs by Gender and Sexual Orientation. Under Review.
4. DeJace J, Nance R, Menza T, Young A, Miller W, Brook D, Feinberg J, Brown R, Baltes A, Pho M, Korthuis PT, Yang WT, **Tsui JI**, Fanucchi L, Nolte K, Stopka T, Romo E, Mixson S; Delaney JC, Friedmann,P. Correlates of Serious Bacterial Infections among Rural Persons Who Inject Drugs, United States, 2018-2020. Under Review.

H. ABSTRACTS

1. Gibbs C, **Tsui J.** A man newly diagnosed with HIV refuses to inform his spouse. Oral Clinical Vignette presented at the 26th SGIM National Meeting, 2003. Vancouver, BC.
2. **Tsui J**, Traub N, Koch-Levy N, Iverson C. Improving access to care for patients with chronic hepatitis C in an inner city hospital: Pairing general internists and specialists. Poster presentation at the 27th SGIM National Meeting, 2004. Chicago, IL
3. **Tsui J**, Pletcher M, Vittinghoff E, Seal K, Gonzales R. Hepatitis C and hospital outcomes in patients admitted with alcohol-related problems. Poster presentation at the 28th SGIM National Meeting, 2005. Chicago, IL.
4. Seal KH, Kral AH, Lorvick J, Gee L, **Tsui J**, Edlin BR. Among injection drug users interest is high, but access low to HCV antiviral therapy. Poster presentation at the 28th SGIM National Meeting, 2005. New Orleans, LA.
5. **Tsui J**, Vittinghoff E, Shlipak M, Rodriguez R, Inadomi J, O'Hare A. Hepatitis C seropositivity is associated with increased risk for developing end-stage renal disease. Oral presentation at the Bay Area Clinic Research Symposium, 2006. San Francisco, CA.

6. **Tsui JI**, Whooley MA, Monto A, Seal K, Tien PC, Shlipak MS. Association of hepatitis C virus seropositivity with inflammatory markers and outcomes in persons with coronary heart disease: Data from the Heart and Soul Study. Poster presentation at the 31th SGIM National Meeting, 2008. Pittsburgh, PA.
7. **Tsui JI**, Maselli J, Gonzales R. Patterns of race and insurance among national ambulatory visits for hepatitis C. Poster presentation at the 31th SGIM National Meeting, 2008. Pittsburgh, PA.
8. **Tsui JI**, Herman DM, Kettavong M, Anderson BJ, Stein MD. Hepatitis C virus infection and chronic pain in opioid-dependent injection drug users. Oral presentation at College on Problems of Drug Dependence 72nd Annual Scientific Meeting, 2010. Scottsdale, AZ.
9. **Tsui JI**, Cheng DM, Coleman SM, Blokhina E, Bridden C, Krupitsky E, Samet JH. Pain is associated with illicit drug use in HIV-infected Russian drinkers. Oral presentation at College on Problems of Drug Dependence 74th Annual Scientific Meeting 2012. Palm Springs, CA.
10. Fuster D, Cheng DM, Quinn EK, Nunes D, Saitz R, Samet JH, **Tsui JI**. Chronic hepatitis C virus (HCV) infection is associated with all-cause mortality in a cohort of HIV-infected patients with alcohol problem. Poster presentation at the 20th Conference on Retroviruses and Opportunistic Infections, 2013. Atlanta, GA.
11. Fuster D, Cheng DM, Quinn EK, Bridden C, Kaku A, Saitz R, Freiberg M, Samet JH, **Tsui JI**. Inflammatory cytokines (IL-6, IL-10 and TNF-alpha) and mortality in a cohort of HIV-infected patients with alcohol problems. Oral presentation at the 20th Conference on Retroviruses and Opportunistic Infections, 2013. Atlanta, GA.
12. **Tsui JI**, Cheng DM, Coleman S, Blokhina E, Bridden C, Krupitsky E, Samet JH. Pain is associated with heavy drinking over time in HIV-infected Russian drinkers. Poster presentation at the 32nd Annual Scientific Meeting of the American Pain Society, 2013. New Orleans, LA.
13. **Tsui JI**, Samet JH, Alcorn MC, Mao J, Edwards RR. Differential predictors of self-reported pain and experimental pain tolerance among treated opioid addicts. Poster presentation at the 32nd Annual Scientific Meeting of the American Pain Society, 2013. New Orleans, LA.
14. **Tsui JI**, Samet JH, Liebschutz J, Alcorn M, Alford D, Mao J, Edwards RR. Depression, Pain catastrophizing and pain tolerance in opioid dependent patients. Poster presentation at the College on Problems of Drug Dependence 75th Annual Scientific Meeting 2013. June 17, 2013. San Diego, CA.
15. **Tsui JI**, Nader C, Pierson L, Labelle C, Pace CA, Samet JH. Integrating care for hepatitis C virus infection with office-based therapy for opioid dependence. Poster presentation at the 37th Annual Meeting of the Society of General Internal Medicine, April 25 2014.
16. **Tsui JI**, Cheng DM, Lira MC, Winter M, Alford D, Mao J, Edwards RR, Samet JH. Hepatitis C virus infection, HIV and pain sensitivity in opioid dependent patients. Oral presentation at the College on Problems of Drug Dependence 76th Annual Scientific Meeting, June 14 2014.
17. Samet JH, Krupitsky E, Wulach L, Chaisson C, **Tsui JI**. Hepatitis C Virus testing and treatment among HIV-infected injection drug users in St. Petersburg, Russia. Oral presentation at the College on Problems of Drug Dependence 76th Annual Scientific Meeting, June 14 2014.
18. **Tsui JI**, Evans JL, Lum PJ, Hahn JA, Page K. Opioid agonist therapy is associated with lower incidence of hepatitis C virus infection in young adult persons who inject drugs. Oral presentation at the American Association of Liver Disease (AASLD) annual meeting, November 2014. Boston MA.
19. **Tsui JI**, Cheng DM, Sisson EK, Bridden C, Merlin JS, Saitz R, Samet JH. Pain and mortality among HIV-infected persons with alcohol problems. Poster at the 34th Annual Scientific Meeting of the American Pain Society, May 13-16, 2015. Palm Springs, CA.
20. **Tsui JI**, Lira M, Cheng DM, Winter MR, Edwards RR, Mao J, Samet JH. Inflammatory cytokines and pain in patients with treated opioid use disorders. Oral presentation at the College on Problems of Drug Dependence 77th Annual Scientific Meeting, June 16 2015.
21. Lira M, Cheng DM, Winter MR, Edwards RR, Samet JH, **Tsui JI**. Chronic pain, craving and recent opioid use among patients treated for opioid use disorders. Poster presentation at the College on Problems of Drug Dependence 77th Annual Scientific Meeting, June 15 2015.
22. **Tsui JI**, Cheng DM, Coleman SM, Blokhina E, Gnatienco N, Bryant K, Krupitsky E, Zvartau E, Samet JH. Pain, alcohol and sex risk behaviors among HIV-infected Russians. Poster presentation at the Research Society on Alcoholism 38th Annual Meeting, June 24 2015. San Antonio TX.
23. **Tsui JI**, Floyd A, Merrill J, Banta-Green C. Barriers to opioid agonist therapy among persons with problematic opioid use. Association for Medical Education and Research in Substance Use 39th Annual National Conference, November 6, 2015. Washington DC.

24. Gnatienco N, **Tsui JI**, Wagman JA, Cheng DM, Raj A, Blokhina E, Toussova O, Forman L, Lioznov D, Samet JH. Gender differences among people who inject drugs with regards to HIV transmission risk in St. Petersburg, Russia. Poster presentation at the 78th College on Problems of Drug Dependence Annual Scientific Meeting & NIDA International Forum, June 11-16, 2016. Palm Springs, CA. Poster presentation at the CHAART 2016 Scientific Meeting, February 7-9, 2016 Washington DC.
25. **Tsui JI**, Glick SN, Thiede H. Utilization of opioid agonist therapy among persons who inject drugs in the Seattle area, Poster presentation at the College on Problems of Drug Dependence 78th Annual Scientific Meeting, June 15 2016.
26. **Tsui JI**, Mirzazadeh A, Hahn JA, Maher L, Bruneau J, Grebely J, Hellard M, Kim AY, Shoukry NH, Cox AL, Prins M, Dore G, Lauer G, Lloyd A, Page K. The effects of alcohol on spontaneous clearance of acute hepatitis c virus infection in females versus males. Poster presentation at the 5th International Symposium on Hepatitis Care in Substance Users, September 6-9, 2016. Oslo, Norway.
27. **Tsui JI**, Peavy M, James J, Merrill JO, Paquin J, Folz B, Chew L, Carney M. An assessment of health care needs among patients and providers in preparation for implementation of on-site primary care services in an opioid treatment program. Oral presentation at the Association for Medical Education and Research in Substance Abuse (AMERSA) 40th Annual National Conference, November 3-5, 2016. Washington, DC.
28. Gordon LM, James JR, Klein JW, Merrill JO, **Tsui JI**. Attitudes toward buprenorphine among staff versus providers in an urban hospital-based primary care clinic. Poster presentation at the Association for Medical Education and Research in Substance Abuse (AMERSA) 40th Annual National Conference, November 3-5, 2016. Washington, DC.
29. James JR, Gordon LM, Klein JW, Merrill JO, **Tsui JI**. Interest in prescribing buprenorphine among residents and attending physicians at an urban hospital-based primary care clinic. Poster presentation at the Association for Medical Education and Research in Substance Abuse (AMERSA) 40th Annual National Conference, November 3-5, 2016. Washington, DC.
30. **Tsui J**, Wagman J, Cheng D, Gnatienco N, Blokhina E, Forman L, Bazzi A, Lioznov D, Samet J. Opportunities for and awareness of pre-exposure prophylaxis among HIV-infected Russian women and men. Poster presentation at the 10th Annual InWomen's Group Conference & NIDA International Forum, June 16, 2017. Montreal, Canada.
31. Assoumou SA, Wang J, **Tsui JI**, Tasillo A, Eftekhari Yazdi G, Linas BP, Strick L. Characterization of a population with hepatitis C virus infection in a U.S. state prison. Poster presentation at the 6th International Symposium on Hepatitis Care in Substance Users (INHSU), September 6-8, 2017. Jersey City, New York.
32. Darnton J, Klein JW, **Tsui JI**. Implementation of Buprenorphine Training for Internal and Family Medicine Residents. Poster Presentation at the Association for Multidisciplinary Education and Research in Substance use and Addiction 42nd Annual National Conference, November 2-4, 2017, Washington, DC.
33. Geddes L, Esmacili A, Iversen J, **Tsui J**, Bruneau J, Shoukry N, Hellard M, Dietze P, Prins M, Morris M, Lloyd A, Maher L, Page K, on behalf of the InC3 Collaboration. Attenuated protective effect of opioid agonist therapy on hepatitis C incidence among females. Oral presentation at the 22nd International Workshop on HIV and Hepatitis Observational Databases, March 22-24, 2018. Fuengirola, Spain.
34. **Tsui JI**, Godersky ME, Merrill JO, Samet JH. Perspectives on Buprenorphine Adherence and Use of mHealth Technology to Address Barriers. Poster presentation at the 49th Annual American Society of Addiction Medicine Conference, April 13, 2018. San Diego, CA.
35. Payne BE, Klein JW, Merrill JO, **Tsui JI**. Ceasing to Require Stimulant Abstinence Increases Engagement in Buprenorphine Treatment. Poster presentation at the 49th American Society of Addiction Medicine Annual Conference, April 13th, 2018, San Diego, CA
36. **Tsui JI**, Lapham G, Boudreau DM, Johnson E, Binswanger IA, Cunningham CO, Thakral M, Arnsten JH, Saxon AJ, Merrill JO, Samet JH, Bart G, Campbell CI, Bradley KA. Opioid use disorder among persons with Hepatitis C and HIV: Data from 8 health systems. Oral presentation at the College on Problems of Drug Addiction Annual Meeting, June 12, 2018. San Diego, CA.
37. Barbosa-Leiker C, Campbell A, Hatch-Maillette M, Lapham G, Boudreau DM, Thakral M, **Tsui J**, Yarborough BJ, Arnsten J, Binswanger I, Stotts A, Loree A, Braciszewski J, Glass J, Horigian V; Hutcheson R, Campbell C, Bart G, Bradley K. Sex differences in co-occurring substance use, mental health and pain disorders, in primary care patients diagnosed with opioid use disorders. Oral presentation at the College on Problems of Drug Addiction Annual Meeting, June 13, 2018. San Diego, CA.

38. Thakral M, Lapham G, Bobb J, **Tsui J**, Boudreau DM, Campbell C, Arnsten J, Liebschutz JM, Stotts A, Braciszewski J, Saxon A, Bradley K. Prevalence of pain conditions among persons with an opioid use disorder diagnosis in a primary care population. Oral presentation at the College on Problems of Drug Addiction Annual Meeting, June 13, 2018. San Diego, CA.
39. Wagman J, Matsuzaki M, Gnatienco N, Metsch LR, Del Rio C, Feaster DJ, Delaney JAC, Dong X, Kahana S, Crane HM, Chandler R, Elliott JC, Altice F, Lucas G, Mehta S, Hirsch-Moverman Y, El-Sadr W, Quan V, Springer S, Pitpitan E, **Tsui JI**, Samet JH. Associations between hazardous alcohol use, antiretroviral receipt and viral suppression in HIV-positive people who inject drugs in the U.S., India, Russia and Vietnam. Poster presentation at 41st Annual RSA Scientific Meeting, June 16-20, 2018. San Diego, CA.
40. Taylor LE, Feinberg J, Norton B, Kim A, Page K, Lum P, Mehta S, **Tsui J**, Litwin A. Real World Direct Acting Antiviral (DAA) Outcomes Among People Who Inject Drugs: Hepatitis C Real Options (HERO). Poster Presentation at the 7th International Symposium on Hepatitis Care in Substance Users, International Network on Hepatitis in Substance Users (INHSU), September 19 – 21, 2018, Lisbon, Portugal.
41. Godersky ME, Merrill JO, Saxon AJ, Samet JH, **Tsui JI**. Feasibility of a mobile health app for video directly observed therapy of buprenorphine among patients treated for opioid use disorders in an office-based setting. Oral Presentation at the Association for Multidisciplinary Education and Research in Substance use and Addiction 42nd Annual National Conference, November 8, 2018, San Francisco, CA
42. Klein JW, Hermesen JL, **Tsui JI**. Linking Infective Endocarditis Patients with Opioid Use Disorder to Addiction Treatment After Valve Replacement. Poster Presentation at the Association for Multidisciplinary Education and Research in Substance use and Addiction 42nd Annual National Conference, November 8, 2018, San Francisco, CA
43. James JR, Chan H, Jackson SI, Sweney G, **Tsui JI**. Primary care based management of chronic hepatitis C by internal medicine trainees. Poster presentation at the Association of Multidisciplinary Education and Research in Substance use and Addiction 42nd Annual National Conference, November 8, 2018, San Francisco, CA
44. **Tsui JI**, Bendiks S, Cheng DM, Blokhina E, Vetrova M, Verbitskaya E, Gnatienco N, Krupitsky E, Samet JH. Pilot study of tolerability and safety of opioid receptor antagonists as novel therapies for pain among HIV-positive Russians with chronic pain and prior heavy drinking. Oral Presentation at the 81st Annual Meeting of the College on Problems of Drug Dependence, Tuesday, June 18, San Antonio, TX.
45. del Rio C, **Tsui J**, Cheng D, Colasanti J, Liebschutz J, Lira M, Forman L, Shanahan C, Root C, Bridden C, Outlaw K, Abrams C, Carroll J, Walley A, Samet J. Targeting Effective Analgesia in Clinics for HIV (TEACH): a Randomized Controlled Trial (RCT) to Improve Satisfaction, Confidence, and Trust around Chronic Opioid Therapy in HIV Care. Poster presentation at the International AIDS Society Meeting, Monday, 22 July 2019, Mexico City, Mexico.
46. Litwin AH, Lum PJ, Taylor LE, Mehta SH, **Tsui JI**, Feinberg J, Kim AY, Norton BL, Heo M, Arnsten J, Meissner P, Karasz A, Mckee MD, Ward JW, Pericot-Valverde I, Agyemang L, Stein E, Thomas A, Borsuk C, Blalock K, Wilkinson S, Wagner K, Roche J, Murray-Krezan C, Jacobsohn V, Page K, and HERO Study Group. A Multi-Site Randomized Pragmatic Trial of Patient-Centered Models of Hepatitis C Treatment for People Who Inject Drugs: The HERO Study. Oral presentation at The Liver Meeting Digital Experience: American Association for the Study of Liver Disease (AASLD), November 16, 2020, virtual meeting.
47. Klein JW, Darnton J, **Tsui JI**, Buprenorphine Waiver Training for Medical Students: Challenges and Missed Opportunities. Poster presentation at the Society of General Internal Medicine NW Regional Meeting, January 23, 2021, virtual meeting.
48. Lyons MS, Chawarski MC, Rothman R, Whiteside L, Cowan C, Richardson LD, Hawk K, **Tsui JI**, Schwartz RP, O'Connor P, D'Onofrio G, Fiellin DA, Edelman JE. Missed HIV and HCV Screening in Emergency Department Patients with Opioid-Use Disorder. Presentation at the Conference on Retroviruses and Opportunistic Infections, March 2021, virtual meeting.
49. **Tsui JI**, Arnsten J, Blalock K, Feinberg J, Kim AY, Lum PJ, Mehta SH, Murray-Krezan C, Norton BL, Perico-Valverde I, Taylor LE, Thomas A, Page K and Litwin AH (co-senior authors) and HERO Study Team. Substance Use and Injecting Behaviors During and After Hepatitis C Treatment Among Persons who Inject Drugs. Workshop presentation at the College of Problems of Drug Dependence Annual Meeting virtual conference, June 23, 2021
50. Ludwig-Barron N, Arnsten J, Blalock K, Feinberg J, Kim A, Litwin A, Lum P, Mehta SP, Page, K, Pericot-Valverde I, Taylor L, **Tsui JI**, HERO Study Team. Self-reported pain before and after cure of hepatitis C among

people who actively inject drugs. Workshop presentation at the College of Problems of Drug Dependence Annual Meeting virtual conference, June 23, 2021

51. **Tsui JI**, Campbell ANC, Pavlicova M, Choo TH, Scodes J, Lee JD, Shulman M, Nunes EV, Rotrosen J. Methamphetamine use over time among persons with opioid use disorders treated with buprenorphine/naloxone versus extended-release naltrexone. Poster presentation at the College of Problems of Drug Dependence 83rd Annual Scientific Meeting virtual conference, June 24, 2021
52. Stephens D, Collins B, Denisiuk E, Merrill JO, Klein J, Hallgren K, Jack H, Blalock K, **Tsui JI**. Methamphetamine Use and Linkage to Outpatient Treatment for Hospitalized Patients Who Initiate Buprenorphine. Addiction Health Services Research Conference, October 14, 2021
53. Radick AC, Schramm ZA, Leroux BG, Blalock KL, Kim TW, **Tsui JI**. Patient characteristics associated with use of video directly-observed therapy for office-based buprenorphine treatment. Poster presentation at the 2021 AMERSA Virtual National Conference. November 3rd, 2021.
54. Klein JW, Schramm ZA, Hallgren KA, Blalock KL, Glick SN, Baldwin L, Graham SM, Merrill JO, Williams EC, **Tsui JI**. Building a Pipeline for Addiction Medicine Research: MedStAR, a Novel Addiction Medicine Research Training Program for Medical Students in Five Western States. Oral presentation at the 2021 AMERSA Virtual National Conference. November 4th, 2021.
55. Williams EC, Austin EJ, Gojic A... **Tsui JI**. Barriers and Facilitators to Implementation of the Pharmacist-Led Model of Hepatitis C Care Delivery for People Who Inject Drugs. Poster presented at the 14th Annual Conference on the Science of Dissemination and Implementation in Health. December 13-14.
56. **Tsui JI**, Whitney BM, Pho M, Jenkins W, Young A, Cooper H, Zule W, Stopka T, de Gijzel, Miller W, Go VF, Korthuis PT, Chan B, Westergaard R, Brown R, Feinberg J, Smith G, Delaney JC, Crane HM, Hagan H, Jenkins R. on behalf of ROI Consortium. Methamphetamine Use and Utilization of Medications for Opioid Use Disorder among Rural People Who Use Drugs. Oral Presentation at the College for Problems on Drug Dependence 84th Annual Scientific Meeting, Minneapolis, MN June 15.
57. Hallgren, K. A., Darnton, J., Soth, S., Blalock, K., Michaels, A., Grekin, P., Saxon, A., Woolworth, S., **Tsui, JI**. Acceptability, feasibility, and clinical outcomes of video observed dosing of methadone take-home doses during the COVID-19 pandemic. Poster presented at the 2022 Society for Prevention Research meeting in Seattle, WA, May 2022.
58. Darnton JB, Bhatraju EP, Beima-Sofie K, Michaels A, Hallgren KA, Soth S, Grekin P, Woolworth S, **Tsui JI**. “Sign Me Up” – A qualitative study of video observation therapy (VOT) for patients receiving expedited methadone take-homes during the COVID-19 pandemic. Poster Presentation at the Association for Multidisciplinary Education and Research in Substance use and Addiction 46th Annual National Conference, November 10, 2022, Boston, MA.
59. **Tsui JI**, Gojic AJ, Pierce KA, Tung EL, Connolly NC, Radick AC, Hunt RR, Sandvold R, Taber K, Kubinieć RH, Scott JD, Hansen RN, Stekler JD, Austin EJ, Williams EC, Glick SN. Feasibility and outcomes of a community pharmacist led program to treat hepatitis C virus among people who inject drugs. Poster, Global Hepatitis Summit, virtual conference April 2023
60. Ross C, Tsui JI, Radick A, Deen J, Buchwald D, Suchy-Dicey A. Prescribed Opioids and Neurocognitive Status Among American Indian Elders: Data from the Strong Heart Study. Poster Presentation at the College for Problems on Drug Dependence 86th Annual Scientific Meeting, Denver CO June 2023

18. INVITED LECTURES AND PRESENTATIONS

- | | |
|------|---|
| 2004 | Invited presentation: “Screening for Hepatitis C” at Primary Care Grand Rounds, Grady Memorial Hospital, Emory University 2004 |
| 2008 | Invited presentation: “Hepatitis C and Kidney Disease Outcomes” at Primary Care Grand Rounds, Mt. Sinai School of Medicine, NY, NY 2008 |
| 2011 | Invited presentation: “Integrating Care for Hepatitis C Virus Infection in Patients Receiving Office-Based Therapy for Opioid Dependence” part of the workshop “Integrating Care for Alcohol and Drug Use in Primary Care: Challenges and Opportunities” at the Addiction Health Services Research Conference, October 4, 2011, Fairfax, VA |
| 2012 | Invited presentation: “Hepatitis C Virus Infection in Injection Drug Users” at the NIDA-sponsored Boston University Fellow Immersion Training (FIT) Program in Addiction, May 2-5, 2012, Chatham MA |

- 2013 Invited presentation: “Chronic Hepatitis C Virus Infection: Not Just a Liver Disease” in NIDA sponsored Symposium “Caring for the Hepatitis C Virus Infected Patient with Co-morbidities” at the 44th American Society of Addiction Medicine Annual Medical-Scientific Conference, April 27, 2013, Chicago, IL
- 2013 Workshop/Invited presentation: “Oh Say Can You C: Training Generalists for Their Roles as Front Line Hepatitis C Screeners, Counselors, and Treaters in the New Era of Birth Cohort Screening” at Society for General Internal Medicine 36th Annual Meeting, April 26, 2013, in Denver, Colorado
- 2014 Panel discussion: “Coping with Addictions: A Patient and Team’s Journey Together” at Department of Medicine Medical Grand Rounds, Schwartz Center Rounds, Boston University March 14, 2014
- 2014 Workshop/Invited presentation: “Impact of Hepatitis C Virus Infection on Quality of Life and Pain” in NIDA sponsored Symposium “Neuropsychiatric Complications of HCV among Drug Users” accepted to the 45th American Society of Addiction Medicine Annual Medical-Scientific Conference, April 11 2014, Orlando, FL
- 2014 Invited presentation: “Hepatitis C Virus Infection for the General Internist: Future Challenges and Opportunities” at General Internal Medicine Grand Rounds, Boston Medical Center May 7, 2014, Boston, MA
- 2015 Invited presentation: “Association of opioid agonist therapy with lower incidence of hepatitis C virus infection in young adult injection drug users” for a Project Echo Hepatitis C Telemedicine conference, March 10, 2015, Seattle, WA
- 2015 Invited presentation: “Pain in patients with HCV & HIV & drug use comorbidity” at Pain and Addiction: Research and Clinical Practice Pre-Conference Session; American Association for Treatment of Opioid Dependence National Conference March 29, 2015, Atlanta, GA
- 2015 Invited presentation: “Organizing and Managing your CV” for Department of Medicine’s Fellows Course, “Surviving and Thriving During the Research Years”, July 29, 2015, Seattle, WA
- 2015 Invited presentation: “Office Based Treatment of Opioid Use Disorders with Buprenorphine” for Community Health Outreach Worker (CHOW) presentation, Public Health – Seattle & King County, November 17, 2015, Seattle Counseling Services, Seattle, WA
- 2016 Invited presentation: “Hepatitis C: A Shifting Paradigm for Patients and Providers” for the HMC Adult Medicine Clinic “Brown Bag” Lectures, November 29, 2016, Seattle, WA
- 2016 Invited presentation: “Hepatitis C: A Shifting Paradigm for Patients and Providers” at Resident Conference/Academic Half-Day, December 1, 2016, Seattle, WA
- 2017 Invited presentation: “Implementing the Massachusetts Model for Opioid Use Disorder Treatment at Harborview” at the 19th Annual Fundamentals of Addiction Medicine Conference jointly sponsored by Providence Regional Medical Center Everett and Swedish Hospital, March 2, 2017
- 2017 Panel discussion: “Hub and Spoke for Delivery of MAT” at Emerging Practices on Collaborative Care Management of Chronic Pain: Equipping Primary Care and the Community to Manage an Epidemic, Collaborative Care Symposium 2017, June 14, 2017, SeaTac, WA
- 2018 Lecturer on “Epidemiology of Substance Use and Substance Use Disorder” for the UWSOM Addiction Medicine Elective course. Jan 22, 2018, Seattle, WA
- 2018 Panel discussion: “Substance use” at Social Determinants of Health, UW/HMC Social Emergency Medicine Conference Day, March 8, 2018, Seattle, WA
- 2018 Invited presentation: CFAR New Faces Seminar: “Access and Adherence to Medications for Opioid Use Disorders and Hepatitis C Among Persons Who Inject Drugs” [[Lecture Recording](#)]
- 2018 Invited presentation “Hepatitis C Elimination and Treatment of HCV Infection Among Persons Who Inject Drugs” for Symposium “The ID Specialist and the Opioid Epidemic: What You Need to Know” IDWeek, San Francisco, Infectious Disease Society of America, October 5, 2018
- 2018 Invited presentation “Practical aspects of caring for patients who inject drugs” and “Treatment of Opioid Use Disorder” at American College of Physicians (ACP) Washington Chapter Scientific Meeting, November 1-3, 2018, Seattle, WA
- 2019 Panel discussion: “HIV, HCV, Opioids, and Meth Use in the Pacific Northwest: Challenges and Opportunities, with special guest Evan Wood” at a Symposium on Substance Use and HIV hosted by UW/FredHutch CFAR Behavioral Science Core, March 13, 2019, Seattle, WA
- 2019 Invited presentation “Alcohol Use and Hepatitis C” for the HepCure Tele-Education Webinar Series, March 16, 2019, presented from Seattle, WA [[Webinar Recording](#)]

- 2019 Panel discussion: “Ask a Medical Provider about Hepatitis C and the Medications that can Cure It” for the HEP C Free WA community event, May 18, 2019, Seattle, WA
- 2019 Invited presentation “Addressing Treatment Gaps to Overcome the Crisis of Opioid Use Disorders and Hepatitis C” at the University of Washington School of Medicine, Department of Medicine Grand Rounds, May 30, 2019, Seattle, WA [[Lecture Recording](#)]
- 2019 “Medications for Opioid Use Disorders and Hepatitis C” for Northwest Addiction Technology Transfer Center webinar, June 26, 2019, presented from Seattle, WA [[Webinar Recording](#)]
- 2019 Invited presentation “The intersection of MOUD work with important health concerns for individuals who smoke and inject drugs.” at Washington Recovery Helpline MOUD Meeting, December 4, 2019, Seattle, WA
- 2020 Lecturer on “Injection Drug Use and Hepatitis C” for graduate student course Conj 556 “Addiction: Mechanisms, Treatment, Prevention” (Dr. Susan Ferguson organizer) presented on March 5, 2020
- 2020 “Medications for Opioid Use Disorder and Hepatitis C: Access for People who Inject Drugs,” virtual lecture for University of Washington MedSTAR Academic Half-Day, July 21, 2020, presented from Seattle, WA
- 2020 “Treating Hepatitis C Among People who use Drugs,” Curriculum developed in collaboration with Washington State Department of Health for buprenorphine waiver training sessions, 3/24/2021
- 2020 Invited presentation, “Closing the Gap in HCV Treatment Disparities for Persons Who Use Drugs: Pilot of a Community Pharmacist-based Program” for King County MAT/OUUDT Providers meeting, September 10, 2020, presented from Seattle, WA
- 2021 Panel discussion, “Quality Medical Care for People who use Drugs” for Providers Clinical Support System webinar attended by 492 live attendees, representing 44 states, District of Columbia, and Puerto Rico, as well as 7 international countries, presented 1/14/2021 from Seattle, WA [[Webinar Recording](#)]
- 2021 Invited presentation, “A pilot randomized controlled trial of a video directly observed therapy intervention delivered via mobile health application to patients receiving office-based opioid use disorder treatment” for CFAR ehealth Work in Progress Meeting, January 21, 2021, presented from Seattle, WA
- 2021 Invited presentation, “Hepatitis C Screening and Treatment for People Who Use Drugs” webinar provided by the UW Alcohol and Drug Abuse Institute, funded by the State Opioid Response (SOR) grant from the Substance Abuse and Mental Health Services Administration (SAMHSA) 1/27/2021
- 2021 Invited presentation, “New Trends in Methamphetamine Use and Treatment Implications for Patients with Opioid Use Disorder” at Addressing the Re-Emerging Stimulant Use Challenge in Patients with and without Opioid Use Disorder Pre-Conference Session; American Association for Treatment of Opioid Dependence National Virtual Conference, April 11, 2021, presented from Seattle, WA
- 2021 Invited presentation, “Treating Hepatitis C Among People who use Drugs and Alcohol” at University of Washington School of Nursing: Hepatitis C Update, April 16, 2021, presented from Seattle WA
- 2021 Invited presentation, “Methamphetamine Use for Persons with Opioid Use Disorder: Implications for Treatment” at NIH HEAL Initiative Virtual Meeting, April 14, 2021, presented from Seattle, WA
- 2021 Invited Workshop, “Community Pharmacy-Based Models to Expand Access to Medications to Address the Opioid Epidemic and the Health of Persons Who Inject Drugs” at the College of Problems of Drug Dependence 83rd Annual Scientific Meeting virtual conference, June 23, 2021
- 2021 Invited presentation, “Treating Hepatitis C Among People Who Use Drugs” on virtual webinar sponsored by Washington Society of Addiction Medicine Approved by the American Society of Addiction Medicine, July 27, 2021 presented from Seattle, WA
- 2021 Invited lecture “Epidemiology of Substance Use and Substance Use Disorder” for the UWSOM Addiction Medicine Elective course. October 12, 2021, Seattle, WA
- 2022 Invited Presentation, “Pharmacist-led Models for Treating Persons Who Inject Drugs for Hepatitis C” UW Project Echo, October 11, 2022
- 2022 Invited lecture, “Epidemiology of Substance Use and Substance Use Disorder” for the UWSOM Addiction Medicine Elective course. October 12, 2022, Seattle, WA
- 2022 Invited Presentation, UW Primary Care Lightning Rounds, “Care for Patients with Hepatitis C to Achieve Elimination Goals” October 19, 2022, Seattle, WA
- 2023 Invited Speaker, “Research Career Trajectories” and “Writing Specific Aims” given to R25 Addiction Medicine fellows at British Columbia Center for Substance Use, Vancouver, WA Jan 20, 2023

- 2023 Invited Workshop facilitator, UW/Fred Hutch CFAR Behavioral Science Care sponsored “Specific Aims Workshop”, Hans Rosling Center for Population Health, UW Feb 3, 2023
- 2023 Invited Presentation “Pharmacist-led Model for Treatment Hepatitis C Among Persons Who Inject Drugs”, CFAR/Fred Hutch Implementation and Science in HIV Research and Practice Symposium 2023, Husky Union Building, UW, Feb 15, 2023
- 2023 Invited Presentation, “Compassionate Addiction Medicine” CME course offered by the Washington State Medical Association, June 16, 2023 (virtual), lectured on “Evidence-based treatment for hepatitis C among persons who use drugs”.
- 2023 Invited Presentation, “Overcoming the Crisis of Opioid Use Disorders and Hepatitis C: Patient-centered Models of Care to Improve Medication Access and Adherence”, Hosted by Rutgers Addiction Research Center (RARC) at the Brain Health Institute (BHI), October 17, 2023 (virtual)

19. OTHER:

N/A